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Executive Summary 
Introduction 
Health Problem 
With 1.4 million cases in 2016 globally, prostate cancer (PC) is the most com-
mon incident cancer for men [1]. The growth of PC is driven by male sex hor-
mones called androgens and even though 80-90% of patients respond to an-
drogen therapy, nearly all eventually develop metastatic castration-resistant 
PC (mCRPC) [2]. The exact number of mCRPC patients is unclear as there 
are no widely accepted criteria for its definition outside of the clinical trial 
setting [3] – the criteria used include the rise in PSA levels, progression of 
existing metastases, or the presence of new metastases [4]. 
The risk for developing PC differs over 50-fold among various world popula-
tions with Western countries leading the incidence rate with one in six men 
[5]. The incidence also increases proportionally with age and is further in-
fluenced by genetic factors, diet, cigarette smoking, hormone levels, and obe-
sity [5, 6]. The natural course of PC is primarily dependent on tumour ag-
gressiveness. PC can remain silent throughout a man’s life without being de-
tected [7], however, if PC grows to the stage of producing symptoms like 
bladder neck obstruction, invasion of adjacent organs, or distant metastasis, 
curative treatment is usually impossible [7]. 
Description of Technology 
177 Lutetium (177Lu) is, to date, the most widely used radioisotope for tar-
geted therapy in PC. Prostate specific membrane antigen (PSMA) is a target 
for radionuclide therapy of PC and its metastases because in the majority of 
PC patients (in more than 90%), it is overexpressed up to 1,000 times [8]. The 
process of labelling of PSMA onto 177Lu can be done in various ways using 
different PSMA peptides and antibodies [9]. In the studies included in this 
assessment, the different types of labelling include three ways of chemical con-
jugation of a peptide, thus three studies used 177Lu-PSMA-DKFZ-617 [10-12], 
one study used 177Lu-PSMA-I&T [13], and the other 177Lu-PSMA-617 [14]. 
177Lu-PSMA has neither CE mark, nor FDA approval. The main claimed ben-
efit is that 177Lu-PSMA offers an extra therapeutic option for mCRPC pa-
tients in the end stage of cancer. Through its targeted approach, 177Lu-PSMA 
claims to reduce the level of prostate specific antigen, have potential survival 
benefits with respect to progression free survival as well as overall survival, and 
have a safe profile that causes a minimal number of grade 3-4 toxicities [15]. 
 
Methods 
The aim of this systematic review was to investigate the use of 177Lu-PSMA 
in mCRPC patients when compared to best supportive care or second line 
therapy or higher (hormonal therapy, chemotherapy, immunotherapy, radio-
pharmaceuticals, and steroids). The question was whether 177Lu-PSMA is 
more effective and safe or equally effective, but safer with respect to the cru-
cial outcomes of overall survival, quality of life, health related quality of life, 
and side effect (study related death, grade 3-4 toxicities, and discontinuation 
rate). The EUnetHTA Core Model for Rapid Assessment of Relative Effec-
tiveness was the main source for selecting relevant assessment elements. 
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The systematic literature search was conducted on the 14-17th of December 
2018 in the four databases (Medline via Ovid, Embase, The Cochrane Library, 
CRD [DARE, NHS-EED, HTA]). The systematic search was not limited to a 
year of publication or to study design, but to articles published in English or 
German. After deduplication, overall 643 citations were included and together 
with eight articles found via hand-search, the overall number of hits was 651. 
A search in three clinical trials registries (ClinicalTrials.gov; WHO-ICTRP; 
EU Clinical Trials) was conducted on the 18.01.2019 and yielded eight po-
tentially relevant hits (out of 36 hits). Manufacturers of the most common 
products (Endocyte®, Scintomics GmbH) were contacted and only Scintom-
ics replied submitting six publications of which no new citations were iden-
tified. 
 
Results 
Available evidence 
No study fulfilled the study inclusion criteria for assessing clinical effective-
ness of the 177Lu-PSMA. RCTs and non-randomised CTs were considered 
for inclusion, but could not be identified through the systematic literature 
search. 
For the analysis of safety, prospective observational evidence was also includ-
ed and hence, we identified five prospective before-after studies that matched 
our inclusion criteria with the total of 141 patients (yet data were reported on 
116 patients) [10-14]. In the absence of data from CTs, no comparisons can 
be made between the 177Lu-PSMA and the comparators. Only intervention 
related complications can be considered for the analysis of safety because the 
effects directly attributable to the intervention can be analysed without a con-
trol group. 
None of the studies was explicitly sponsored by the any of the manufactur-
ers, but a member of the authoring team in one study was a shareholder at 
Scintomics, Germany [13]. One study had no funding [11], another study was 
funded by Peter MacCallum Foundation and Prostate Cancer Foundation 
[12], another by University of Innsbruck and Medical University of Innsbruck 
[14], and the last by Paul Ramsey Foundation [10]. Clinical follow-up was un-
clear in two studies [10, 14], and ranged from mean 13 to median 25 months 
in the remaining 3 studies [11-13]. 
Clinical effectiveness 
No evidence was found to answer the question of clinical effectiveness  
of 177Lu-PSMA. 
Safety 
Concerning serious adverse events (SAEs), the outcome of study related death 
was reported in two studies and it did not occur in either [12, 13]. Concern-
ing adverse events (AEs), the outcomes of discontinuation rate was reported 
in one study where no patients discontinued treatment [12]. With respect to 
grade 3-4 toxicities, nephrotoxicity was reported in four studies, but did not 
occur either [11-14]. With respect to hematotoxicity: lymphocytopenia was re-
ported in three studies [12-14] and occurred in one in 37% of patients [12], 
thrombocytopenia and anaemia were both reported in four studies [10, 12-14] 
and both occurred in one in 13% of patients [12], neutropenia was reported  
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in three studies [12-14] and occurred in one in 7% of patients [12], and hae-
moglobin toxicity was reported in one study in 3.2% of patients [11]. Hepato-
toxicity was reported in two studies, but did not occur in either [11, 14], while 
bone pain flare was reported in one study and occurred in 3% of patients [12]. 
As 177Lu-PSMA is a therapy that targets the specific antigen expressed on 
the surface of PC tumour cells as well as on other cells such as kidneys, liver, 
spleen, bone marrow, salivary, lacrimal, and parotid glands, the precision of 
177Lu-PSMA therapy is important. There is no agreement on which of the 
above organs is the main dose limiting one and hence which one is most sus-
ceptible to harms related dosage of 177Lu-PSMA, which stresses the impor-
tance of patient specific dosimetry [15-19]. 
Upcoming evidence 
At this point in time, the manufacturer Endocyte® is in the process of apply-
ing for an FDA approval with their ongoing RCT comparing 177Lu-PSMA 
to best standard care (NCT03511664). One further RCT (NCT03392428) 
comparing 177Lu-PSMA to the chemotherapy cabazitaxel is also in the re-
cruiting phase.  
Reimbursement 
Up until the end of 2018, 177Lu-PSMA was performed under either clinical 
trials or under local regulations for unproven interventions for patients who 
have exhausted all therapeutic options [20]. Since 2019, 177Lu-PSMA is in-
cluded in the German DRG system [21]. 
 
Discussion 
Overall, the strength of evidence for clinical effectiveness was not assessed 
due to the lack of controlled studies. Regarding safety of 177Lu-PSMA, the 
quality of evidence was low (for outcomes of study related death and discon-
tinuation rate) to very low (for the outcome of grade 3-4 toxicities). 
Challenges with interpreting the data arise when we take into consideration 
the extent to which the patient population was pre-treated before the admin-
istration of 177Lu-PSMA, where previous interventions include hormone 
therapy, luteinizing hormone-releasing hormone (LHRH) agents, external 
beam radiation, surgical therapy, chemotherapy, antiandrogens, and bone in-
terventions. Hence, in the light of the lack of controlled data, assigning the ef-
fects observed to 177Lu-PSMA is questionable. Also, interpreting the data is 
especially problematic in the light of only one study reporting on the base-
line toxicity data [11] and only two studies reporting on the co-interventions 
that patients continued on during the course of 177Lu-PSMA, which ranged 
from blood transfusions to bone interventions, palliative radiotherapy, anti-
androgens, and LHRH agents [10, 12]. Furthermore, it remains unclear why 
all reported instances of AEs – except for haemoglobin toxicity [11] – occur-
red in only one study that acknowledged the co-interventions used, had the 
best standard of reporting, longest follow-up, and the lowest risk of bias [12]. 
In terms of external validity, the data is considered generalizable to the Aus-
trian context as the countries of recruitment were Germany, Australia, Aus-
tria, and India. At the same time, however, as the Austrian context allows for 
the administration of 177Lu-PSMA also in the outpatient setting, none of the 
studies included reported data from this context and hence in this respect, no 
conclusions can be made.  
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The evidence found only partially answered our research questions. The pro-
spective observational evidence found can only contribute to the safety assess-
ment, yet still with a low to very low quality of evidence. RCTs or CTs com-
paring 177Lu-PSMA to alternative treatment options are thus necessary. How-
ever, choosing the right comparator presents a challenge. On the one hand, 
177Lu-PSMA, as an experimental therapy, is to be used after the exhaustion 
of all therapeutic options (as it was the case in the studies included in the 
analysis), yet on the other hand, German AWMF S3 guideline includes 177-
Lu-PSMA in the category of second line therapies [22]. 
 
Recommendation 
The inclusion in the catalogue of benefits is currently not recommended.  
The current evidence is not sufficient to prove that the assessed technology 
177Lu-PSMA is more effective and equally safe or equally effective, but saf-
er than the comparators of best supportive care or the second line therapies: 
hormonal therapy, chemotherapy, immunotherapy, radiopharmaceuticals, or 
steroids. New study results will potentially influence the effect estimate con-
siderably. The re-evaluation is recommended in 2021 after the completion of 
two ongoing RCTs (NCT03392428, NCT03511664). 
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Zusammenfassung 
Einleitung 
Indikation und therapeutisches Ziel 
Prostatakrebs (PC) ist mit 1,4 Millionen Fällen im Jahr 2016 die häufigste 
Krebserkrankung unter Männern [1] Beim Wachstum von Prostatakarzino-
men spielen die männlichen Sexualhormone, Androgene, eine wichtige Rol-
le. Obwohl 80-90 % der Patienten auf eine Antiandrogentherapie ansprechen, 
entwickeln bis auf wenige Ausnahmen ein metastasiertes kastrationsresisten-
tes Prostatakarzinom (mCRPC) [2]. Die genaue Anzahl an mCRPC-erkrank-
ten Patienten ist aufgrund fehlender Kriterien für eine Definition einer mCR-
PC-Erkrankung außerhalb des klinischen Versuchssettings unklar [3]. Ange-
wendete Kriterien beinhalten den Anstieg des prostataspezifischen Antigens 
(PSA), Progression von existierenden Metastasen, oder das Vorhandensein 
neuer Metastasen [4]. 
Bezüglich des Auftretens von Prostatakarzinomen weltweit kann es zu Un-
terschieden kommen, welche in manchen Fällen um das 50-fache variieren. 
Hinsichtlich der Inzidenz sind westliche Staaten mit Raten von einem in sechs 
Männern führend. Zusätzlich nimmt die Inzidenz mit steigendem Alter pro-
portional zu. Auch genetische Faktoren, Ernährungsgewohnheiten, Rauchen, 
der Hormonspiegel und Übergewicht beeinflussen das Auftreten von PC [5, 
6]. Der Verlauf eines PC ist hauptsächlich von der Aggressivität des Tumors 
abhängig. Häufig verläuft das Wachstum von Prostatakrebs langsam und un-
auffällig, ohne dass er jedoch erkannt wird. Wenn PC allerdings bis zu einem 
Stadium wächst, in dem Symptome wie Blasenhalsobstruktion, die Ausbrei-
tung der Krebszellen vom Primärtumor zu angrenzenden Organen, oder Fern-
metastasen auftreten, dann ist eine kurative Behandlung meistens nicht mehr 
möglich [7]. 
Beschreibung der Technologie 
177Lutetium (177Lu) ist das am häufigsten verwendete Radioisotop für eine 
zielgerichtete Therapie von PC. Eine Radionuklidtherapie zielt dabei auf eine 
Reduktion des prostataspezifischen Membranantigens (PSMA) des PC und 
der Metastasen ab, da in den meisten Patienten (mehr als 90 %) das Antigen 
um das 1.000-fache erhöht ist [8]. Die Kennzeichnung von PSMA durch 177Lu 
kann in verschiedenen Varianten mit unterschiedlichen PSMA-Peptiden und 
-Antikörpern durchgeführt werden [9]. In den eingeschlossen Studien dieses 
Assessment werden drei Ansätze chemischer Konjugation eingesetzt: 177Lu-
PSMA-DKFZ-617 [10-12], 177Lu-PSMA-I&T [13], und 177Lu-PSMA-617 
[14]. 
177Lu-PSMA hat weder ein CE-Kennzeichnung, noch eine FDA Zulassung. 
Der vermeintliche Nutzen von 177Lu-PSMA soll vor allem in der Therapie 
von PC-Patienten im Endstadium liegen. Dabei soll aufgrund des zielge-
richteten Therapieansatzes das prostataspezifische Antigen reduziert und das 
Überleben, sowohl hinsichtlich des progressionsfreien-Überlebens (PFS) und 
des Gesamtüberlebens, verlängert werden. Die 177Lu-PSMA Therapie soll 
weiters ein sicheres Nebenwirkungsprofil und einer geringen Anzahl an Grad 
3-4 Nebenwirkungen aufweisen [15]. 
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Methoden 
Das Ziel dieser systematischen Übersichtsarbeit war es, den Einsatz von 177-
Lu-PSMA versus Best Supportive Care als Zweitlinientherapie oder höher 
(Hormontherapie, Chemotherapie, Immunotherapie, radiopharmazeutischen 
Medikamente und Steroide) zu untersuchen. Folglich sollte festgestellt wer-
den, ob 177Lu-PSMA wirksamer und sicherer oder gleich effektiv ist, insbe-
sondere im Hinblick auf OS, Lebensqualität, gesundheitsbezogene Lebens-
qualität und Nebenwirkungen (studienbezogene Todesfälle, Grad 3-4 Toxi-
zitäten und Therapieabbruchraten). Das EUnetHTA Core Model für Rapid 
Assessment of Relative Effectiveness diente als Basis für die Auswahl rele-
vanter Bewertungselemente. 
Die systematische Literatursuche wurde zwischen dem 14. und 17. Dezem-
ber 2018 in vier Datenbanken durchgeführt (Medline via Ovid, Embase, The 
Cochrane Library, CRD [DARE, NHS-EED, HTA]). Die Literatursuche be-
schränkte sich nicht auf ein Publikationsjahr oder Studiendesign, jedoch gab 
es sprachliche Einschränkungen auf englische und deutsche Artikel. Nach 
der Deduplikation wurden 643 Zitate zusammen mit acht weiteren Artikeln 
(Handsuche) in das Assessment eingeschlossen. Somit lag die Gesamtanzahl 
der Treffer bei 651. 
Eine Suche in drei klinischen Studienregistern (ClinicalTrials.gov; WHO-
ICTRP; EU Clinical Trials) wurde am 18.01.2019 durchgeführt. Diese Suche 
ergab acht potentiell relevante Treffer (von 36 Treffern). Die Hersteller der 
geläufigsten Produkte (Endocyte®, Scintomics GmbH) wurden kontaktiert, von 
denen nur Scintomics antwortete und sechs Publikation bereitstellte, wobei 
diese bereits identifiziert wurden. 
 
Ergebnisse 
Verfügbare Evidenz 
Keine der identifizierten Studien erfüllte die Einschlusskriterien für eine Be-
wertung der klinischen Wirksamkeit von 177Lu-PSMA. Es hätten randomi-
sierte kontrollierte Studien und nicht-randomisierte kontrollierte Studien be-
rücksichtigt werden sollen, diese konnten jedoch nicht durch die systemati-
sche Literaturrecherche ermittelt werden. 
Für die Analyse hinsichtlich der Sicherheit wurden prospektive Beobachtungs-
studien eingeschlossen. Es konnten fünf prospektive Vorher-Nachher-Studien 
mit insgesamt 141 Patienten (Daten wurden nur für 116 berichtet) identifiziert 
werden, welche den Einschlusskriterien entsprachen [10-14]. Ohne kontrol-
lierte Studien kann kein Vergleich zwischen 177Lu-PSMA und den Kompa-
ratoren angestellt werden. Ausschließlich Komplikationen, welche die Inter-
vention betreffen, können für die Analyse berücksichtigt werden. Da Aus-
wirkungen, welche direkt auf die Intervention zurückzuführen sind auch ohne 
Vergleichsgruppe analysiert werden können. 
Keine der Studien wurde explizit durch einen Hersteller finanziert. Allerdings 
war ein Mitglied des Autorenteams einer Studie Aktionär bei Scintomics 
GmbH, Deutschland [13]. Eine der Studien hatte keine Förderungen [11], ei-
ne andere wurde durch die Peter MacCallum Foundation and Prostate Cancer 
Foundation finanziert [12], eine weitere Studie durch die Universität Inns-
bruck und durch die Medizinische Universität Innsbruck [14]. Die letzte Stu-
die wurde durch die Paul Ramsey Foundation gefördert [10]. Bei zwei Stu-
dien war die Follow-Up Zeit unklar [10, 14]. In den anderen drei Studien reich-
te die Follow-Up Zeit von 13 (Mittelwert) bis 25 (Median) Monaten [11-13]. 
Ziel: Ist 177Lu-PSMA vs. 
Best Supportive Care als 
Zweitlinientherapie 
(oder höher) wirksamer 
und sicherer? 
systematische Suche in 
4 Datenbanken;  
651 Gesamttreffer 
Suche nach laufenden 
Studien in 3 klinischen 
Studienregistern 
keine Studie für eine 
Analyse der klinischen 
Effektivität lag vor 
5 prospektive Vorher-
Nacher-Studien für die 
Analyse der Sicherheit 
mit 141 Patienten  
(116 berichtet) wurden 
eingeschlossen 
keine Studie wurde 
durch einen Hersteller 
finanziert;  
Follow-Up von  
13 (Mittelwert) bis 25 
(Median) Monaten 
Zusammenfassung 
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Klinische Wirksamkeit 
Es konnte keine Evidenz für die klinische Wirksamkeit für 177Lu-PSMA 
gefunden werden. 
Sicherheit 
In zwei Studien [12, 13] wurden, in Hinsicht auf schwerwiegende unerwünsch-
te Ereignisse (SAE), studienbezogene Todesfälle untersucht, jedoch traten 
diese nicht auf. In Bezug auf Nebenwirkungen (AEs) untersuchte eine Studie 
die Abbruchrate von Patienten, wenngleich diese nicht auftrat [12]. Hinsicht-
lich Grad 3-4 Toxizität wurde Nephrotoxizität in vier Studien untersucht, trat 
aber in keiner der Studien auf [11-14]. Mit Bezug auf Hematoxizität wurde 
eine Lymphozytopenie in drei Studien berichtet [12-14] und trat in einer Stu-
die in 37 % der Patienten auf [12]. Thrombozytopenie und Anämie wurden 
in vier Studien berichtet [10, 12-14] und beide Nebenwirkungen traten in 
einer Studie in 13 % der Patienten auf [12]. Neutropenie wurde in drei Stu-
dien berichtet [12-14] und trat in einer Studie in 7 % der Patienten auf [12]. 
Eine Studie [11] berichtete eine Haemoglobintoxizität in 3,2 % der Patienten. 
Zwei Studien berichteten über Hepatoxizität [11-14], welche aber in beiden 
Fällen nicht auftraten, während aufkommende Knochenschmerzen in einer 
Studie mit einem Anteil von 3 % der Patienten berichtet wurden [12]. 
PSMA wird an der Oberfläche von PC-Tumorzellen exprimiert und dient als 
molekulares Target der 177Lu-PSMA-Therapie. Dabei spielt die Präzision 
der Therapie eine wichtige Rolle, da auch andere Zellen z. B.: der Niere, Le-
ber, Milz, im Knochenmark, der Speicheldrüse, Tränendrüse und Ohrspei-
cheldrüse, von der Therapie betroffen sein können. Es gibt allerdings keinen 
Konsens darüber, welches der oben angeführten Organe für eine Dosislimi-
tierung herangezogen werden sollte. Auch herrscht keine klare Einigkeit da-
rüber, welches das empfindlichste Organ für Schäden hinsichtlich der Do-
sierung darstellt. Folglich ist eine patientenspezifische Dosimetrie von be-
sonderer Bedeutung [15-19]. 
Laufende Studien 
Zu diesem Zeitpunkt ist der Hersteller Endocyte® im Prozess eine FDA-Zu-
lassung mit ihrer laufenden randomisierten kontrollierten Studie zu bean-
tragen. Diese Studie vergleicht die 177Lu-PSMA Therapie mit dem besten 
Behandlungsstandard (NCT03511664). Eine weitere randomisierte kontrol-
lierte Studie (NCT03392428) befindet sich in der Rekrutierungsphase und 
vergleicht die 177Lu-PSMA-Therapie mit der Chemotherapie Cabazitaxel. 
Kostenerstattung 
Bis zum Ende des Jahres 2018 wurde die 177Lu-PSMA-Therapie entweder 
in klinischen Studiensettings oder gemäß lokaler Bestimmungen für nicht 
ausreichend untersuchter Interventionen für Patienten, welche bereits alle 
therapeutischen Optionen [20] ausgeschöpft haben, eingesetzt. Seit 2019 ist 
die Therapie mit 177Lu-PSMA im deutschen DRG-System gelistet [21]. 
 
Diskussion 
Im Allgemeinen wurde die Evidenzstärke für die klinische Wirksamkeit nicht 
beurteilt, da bis dato keine qualitativ hochwertigen kontrollierten Studien ver-
fügbar sind. In Bezug auf die Sicherheit von 177Lu-PSMA wurde die Quali-
tät der Evidenz als niedrig (studienbezogene Todesfälle und Abbruchraten 
der Therapie) bis sehr niedrig (Grad 3-4 Toxizitäten) eingestuft. 
keine Evidenz gefunden 
SAEs traten in  
keiner Studie auf;  
kein Abbruch der 
Therapie 
 
Grad 3-4 Toxizitäten: 
keine Hepatptoxizität 
und Nephrotoxizität; 
Hematoxizität und 
Haemoglobintoxizität 
wurden in 3,2-37 %  
der Patienten in den 
jeweiligen Studien 
berichtet 
Präzision der Therapie 
ist mit Blick auf das 
dosislimitierende Organ 
von Bedeutung 
 
patientenspezifische 
Dosimetrie ist von 
besonderer Bedeutung 
2 laufende RCTs:  
eine mit bestmöglicher 
unterstützender 
Behandlung, die andere 
mit Cabazitaxel 
in Deutschland seit  
2019 erstattungsfähig 
Qualität der Evidenz  
für Sicherheit ist niedrig 
bis sehr niedrig 
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Die Interpretation der Ergebnisse wird durch die jeweilige Vorbehandlung 
der Patienten, wie bspw. Hormontherapie, luteinisierende Hormon Releasing-
Hormon-Wirkstofftherapie (LHRH), externe Bestrahlungstherapie, operative 
Therapie, Chemotherapie, Antiandrogentherapie und Knocheneingriffe, er-
schwert. Folglich ist eine direkte Zuordnung der beobachteten Effekte von 
177Lu-PSMA ohne kontrollierte Daten nicht möglich. Zusätzlich wird die 
Interpretation der Daten erschwert, da nur eine Studie Daten zur Baseline-
Toxizität [11] und nur zwei Studien über Begleitinterventionen, welche Pa-
tienten während der Therapie mit 177Lu-PSMA durchliefen, berichtet. Da-
zu gehörten Bluttransfusionen bis hin zu Knocheneingriffe, palliative Radio-
therapie, Antiandrogentherapie und Therapien mit LHRH-Wirkstoffen [10, 
12]. Zusätzlich bleibt unklar, warum alle berichteten Fälle von AEs – außer 
Haemoglobintoxizität [11] – ausschließlich in einer Studie eintraten. Hinzu-
kommend war diese Studie auch die einzige, welche die angewendeten Ko-
Interventionen berücksichtigte, den höchsten Standard hinsichtlich der Be-
richtsqualität, die längste Follow-Up Periode und das niedrigste Risiko eines 
Bias aufwies [12]. 
Hinsichtlich der externen Validität sind die Daten auf den österreichischen 
Kontext übertragbar. Die Rekrutierung der Patienten wurde in Deutschland, 
Australien, Österreich und Indien durchgeführt. Im österreichischen Kontext 
kann die Anwendung von 177Lu-PSMA auch im niedergelassenen Bereich 
durchgeführt werden, jedoch lag keine Evidenz zu diesem Kontext vor. Folg-
lich können auch keine Schlussfolgerungen zu diesem Behandlungssetting 
abgegeben werden. 
Die untersuchte Evidenz erlaubte es uns, unsere Forschungsfrage nur teil-
weise zu beantworten. Aufgrund der ausschließlichen Evidenz aus prospek-
tiven Beobachtungsstudien, lässt sich nur eine Einschätzung hinsichtlich der 
Sicherheit abgeben. Diese ist jedoch auch nur auf Grundlage niedriger bis 
sehr niedriger Qualität hinsichtlich der Evidenz möglich. Aufgrund dessen 
sind randomisierte kontrollierte oder kontrollierte Studien, welche einen Ver-
gleich von 177Lu-PSMA mit einer alternativen Intervention durchführen, 
nötig. Allerdings stellt die richtige Wahl des Komparators eine Herausforde-
rung dar. So stellt 177Lu-PSMA einerseits eine experimentelle Therapie dar 
und wird nach Ausschöpfung aller relevanten therapeutischen Alternativen 
in Betracht gezogen, andererseits wird die 177Lu-PSMA-Therapie in der 
deutschen AWMF S3 Leitlinie als Zweitlinientherapie empfohlen [22]. 
 
Empfehlung  
Eine Aufnahme in den Leistungskatalog wird derzeit nicht empfohlen. 
Die momentane Evidenz der 177Lu-PSMA-Technologie ist nicht hinreichend, 
um zu belegen, dass die Therapie mit 177Lu-PSMA wirksamer und gleicher-
maßen sicher oder gleichermaßen wirksam, aber sicherer als die zu Verfü-
gung stehenden Komparatoren (Best Supportive Care) oder Zweitlinienthe-
rapien (Hormontherapie, Chemotherapie, Immunotherapie, radiopharamzeu-
tische Therapie oder Steroide) ist. Ergebnisse zukünftiger Studien können 
potentiell den Effektschätzer maßgeblich beeinflussen. Eine Re-Evaluation 
ist im Jahr 2021 nach der Beendigung von zwei laufenden randomisierten 
kontrollierten Studien empfohlen (NCT03392428, NCT03511664). 
 
Herausforderung  
bei der Interpretation 
der Daten:  
stark vorbehandelte 
Population, Baseline-
Toxizität, Mangel an 
Berichterstattung von 
Ko-Interventionen 
Daten sind auf den 
österreichischen 
Kontext generalisierbar; 
Studien liefern keine 
Daten über den Einsatz 
im niedergelassenen 
Bereich 
weitere kontrollierte 
Studien sind nötig; 
Mehrdeutigkeit 
hinsichtlich der 
Komparatoren und  
der Therapielinie 
Aufnahme in den 
Leistungskatalog derzeit 
nicht empfohlen 
 
 
Re-Evaluation im Jahr 
2021 wird empfohlen 
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1 Scope 
1.1 PICO question 
Is Lutetium-177 labelled Prostate-Specific Membrane Antigen (PSMA) in-
hibitor therapy in comparison to best supportive care or second line therapy 
(hormonal therapy, chemotherapy, immunotherapy, radiopharmaceuticals, 
steroids) in patients with castration-resistant metastatic prostate cancer more 
effective and safe or equally effective, but safer concerning overall survival 
(OS), quality of life (QoL), and health related quality of life (HRQoL) and 
side effects? 
 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarized in Table 1-1. 
Table 1-1: Inclusion criteria 
Population Fourth line therapy (third line in case that patients are ineligible for chemotherapy) after 
exhaustion of all therapeutic options for male patients (≥18 years old) with castration-resistant/ 
recurrent metastatic prostate cancer (CRPC or CRMPC). CRPC can also be called hormone-
resistant prostate cancer (HRPC) or androgen-insensitive/independent prostate cancer (AIPC). 
ICD-10 Code: C61 
MeSH-terms:Prostate, Neoplasms, Prostatic Neoplasms, Neoplasm Metastasis, Castration, 
Castration-Resistant 
Intervention Lutetium (Lu)-177-labelled Prostate-Specific Membrane Antigen (PSMA) Inhibitor Therapy 
administered intravenously. PSMA can be also called folate hydrolase I or glutamate 
carboxypeptidase II. 
Available agents: 
 177LU-PSMA-617 (Endocyte®, Indiana, USA) 
 177LU-PSMA-I&T (Scintomics GmbH, Fürstenfeldbruck, Germany) 
 alternatively, own agents made by radiopharmacists 
MeSH-terms: Lutetium, Prostate, Antigens, Therapeutics, Lutetium-177, Ligands, 
Radioisotopes, radiopharmaceuticals 
Keine MeSH: radioligand therapy 
Control Best supportive/best standard of care (incl. registered treatments at physician’s choice as 
well as palliative care such as mitigation of pain, fatigue, loss of weight, fear, depression ...) 
Second line therapy or higher (≥2nd-line) 
 Hormonal therapy 
 Abiraterone (Zytiga) alone or in combination with prednisone 
 Enzalutamide (Xtandi) 
 Chemotherapy  
 Docetaxel (Docefrez/Taxotere) + prednisone  
 Cabazitaxel (Jevtana)  
 Mitoxantrone (Novantrone) 
 Estramustine ( Emcyt) 
 Immunotherapy 
 Sipuleucel-T (Provenge) 
 
PIKO-Frage 
Einschlusskriterien  
für relevante Studien 
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Control 
(continuation) 
 Radiopharmaceuticals 
 Radium 223 (Xofigo)  
 Steroids 
 Dexamethasone 
 Prednisolone 
 Prednisone  
MeSH-terms: Pharmaceutical Preparations, Immunotherapy, Drug Therapy, Antigens, 
Prostatic Neoplasms, Bone and Bones, Palliative Care 
Outcomes  
Efficacy Clinical endpoints: 
 Overall survival (OS) (time from randomization until death from any cause) 
 Quality of Life (QoL) – measures aspects of an individual’s sense of well-being and ability 
to carry out activities of daily living) 
 The European Organisation for Research and Treatment of Cancer (EORTC-Q30) 
 Eastern Cooperative Oncology Group (ECOG) 
 Karnofsky Performance Status (KPS) 
 Pain scores (a scale for rating pain) 
 Brief Pain Inventory Short-Form (BPI-SF)  
 Visual Analogue Scale (VAS) 
 Health Related Quality of Life (HRQoL) (measures aspects of an individual’s sense  
of well-being with respect to physical and mental health) 
 Functional Assessment of Cancer Therapy – Prostate cancer (FACT-P) 
Surrogate endpoints: 
 Progression free survival (PFS) (radiographically/otherwised confirmed progression  
free survival-(FDG)PET/CT/MRI/SPECT) 
 Response evaluation criteria in solid tumors (RECIST) response (a method measuring 
patients’ response to treatment: when tumors improve (“respond”), stay the same 
(“stabilize”), or worsen (“progress”) during treatment) 
 Prostate Specific Antigen (PSA) PFS (progresson free survival as measured by the 
prostate specific membrane antigen levels) 
Safety Serious adverse events (SAEs): 
 Study related death 
Adverse events (AEs): 
 All grade 3-4 toxicities related to the treatment i.e. nephrotoxicity, hematotoxicity, 
hepatotoxicity bone pain flare etc. (as measured by Common Terminology Criteria  
for Adverse Events (CTCAE) version 5.0) 
 Discontinuation rates 
Study design  
Efficacy Randomised controlled trials 
Prospective non-randomised controlled trials 
Safety Randomised controlled trials 
Prospective non-randomised controlled trials 
Prospective case-series (single arm studies, registries ... etc.) 
(No minimum number of patients requird, but individual case report excluded) 
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2 Methods 
2.1 Research questions 
Description of the technology 
Element ID Research question 
B0001 What is 177Lu-PSMA and the comparators? 
A0020 For which indications has 177Lu-PSMA received marketing authorisation or CE marking? 
B0002 What is the claimed benefit of 177Lu-PSMA in relation to the comparators? 
B0003 What is the phase of development and implementation of 177Lu-PSMA and the comparators? 
B0004 Who administers 177Lu-PSMA and the comparators and in what context and level of care  
are they provided? 
B0008 What kind of special premises are needed to use 177Lu-PSMA and the comparators? 
B0009 What supplies are needed to use 177Lu-PSMA and the comparators? 
A0021 What is the reimbursement status of 177Lu-PSMA? 
 
Health problem and Current Use 
Element ID Research question 
A0001 For which health conditions, and for what purposes is 177Lu-PSMA used? 
A0002 What is the disease or health condition in the scope of this assessment? 
A0003 What are the known risk factors for mCRPC? 
A0004 What is the natural course of mCRPC? 
A0005 What is the burden of disease for the patients with mCRPC? 
A0006 What are the consequences of mCRPC for the society? 
A0024 How is mCRPC currently diagnosed according to published guidelines and in practice? 
A0025 How is mCRPC currently managed according to published guidelines and in practice? 
A0007 What is the target population in this assessment?  
A0023 How many people belong to the target population? 
A0011 How much is 177Lu-PSMA utilised? 
 
Clinical Effectiveness 
Element ID Research question 
D0001 What is the expected beneficial effect of 177Lu-PSMA on mortality? 
D0003 What is the effect of 177Lu-PSMA on the mortality due to causes other than mCRPC? 
D0005 How does 177Lu-PSMA affect symptoms and findings (severity, frequency) of mCRPC? 
D0006 How does 177Lu-PSMA affect progression (or recurrence) of mCRPC? 
D0011 What is the effect of 177Lu-PSMA on patients’ body functions? 
D0016 How does the use of 177Lu-PSMA affect activities of daily living? 
D0012 What is the effect of 177Lu-PSMA on generic health-related quality of life? 
D0013 What is the effect of 177Lu-PSMA on disease-specific quality of life? 
D0017 Was the use of 177Lu-PSMA worthwhile? 
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Safety 
Element ID Research question 
C0008 How safe is 177Lu-PSMA in comparison to the comparators? 
C0002 Are the harms related to dosage or frequency of applying 177Lu-PSMA? 
C0004 How does the frequency or severity of harms change over time or in different settings? 
C0005 What are the susceptible patient groups that are more likely to be harmed through  
the use of 177Lu-PSMA? 
C0007 Are 177Lu-PSMA and comparators associated with user-dependent harms? 
B0010 What kind of data/records and/or registry is needed to monitor the use of 177Lu-PSMA  
and the comparator? 
 
 
2.2 Sources 
Description of the technology 
 Handsearch in the POP, AdHopHTA and CRD databases  
for Health Technology Assessments 
 Background publications identified in database search: see Section 2.3 
 Documentation provided by the manufacturers 
 Questionnaire completed by the submitting hospital 
Health problem and Current Use 
 Handsearch in the POP, AdHopHTA and CRD databases  
for Health Technology Assessments 
 Background publications identified in database search: see Section 2.3 
 Documentation provided by the manufacturers 
 Questionnaire completed by the submitting hospital  
 
 
2.3 Systematic literature search 
The systematic literature search was conducted on the  
14-17th of December 2018 in the following databases:  
 Medline via Ovid 
 Embase  
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA) 
The systematic search was not limited to a year of publication or to study 
design, but to articles published in English or German. After deduplication, 
overall 643 citations were included. The specific search strategy employed 
can be found in the Appendix. 
 
Quellen:  
systematische Suche, 
Handsuche sowie 
Informationen des 
einreichenden 
Krankenhauses 
systematische 
Literatursuche in  
4 Datenbanken  
Methods 
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Furthermore, to identify ongoing and unpublished studies, a search in three 
clinical trials registries (ClinicalTrials.gov; WHO-ICTRP; EU Clinical Trials) 
was conducted on the 18.01.2019 resulting in eight potentially relevant hits. 
Manufacturers of the most common products (Endocyte®, Scintomics GmbH) 
were contacted and only Scintomics replied submitting six publications of 
which no new citations were identified.  
By hand-search an additional eight were found, resulting in overall 651 hits. 
 
 
2.4 Flow chart of study selection 
Overall 643 hits were identified. The references were screened by two inde-
pendent researchers and in case of disagreement a third researcher was in-
volved to solve the differences. The selection process is displayed in Figure 
2-1. 
 
Figure 2-1: Flow chart of study selection (PRISMA Flow Diagram) 
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(n=651) 
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(n=571) 
Full-text articles  
assessed for eligibility 
(n=80) 
Full-text articles excluded,  
with reasons 
(n=75) 
 Abstracts (n=28) 
 Background literature (n=25) 
 SRs including other study 
designs (n=4) 
 Other study design (n=16) 
 Ongoing trials (n=2) 
Studies included in 
qualitative synthesis 
(n=5) 
 Case-series (n=5) 
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2.5 Analysis 
The data retrieved from the selected studies were systematically extracted 
into a data-extraction-table (see Table A-1). No further data processing (e.g. 
indirect comparison) was applied. Three independent researchers (MS, NG, 
CS) systematically assessed the quality of evidence (see Table 7-1) and the 
risk of bias (RoB) using the checklists presented in the Table A-2. 
 
 
2.6 Synthesis 
Based on the data-extraction-table (see Table A-1), data on each selected out-
come category were synthesised across studies according to GRADE (Grad-
ing of Recommendations Assessment, Development and Evaluation) [23]. 
The research questions were answered in plain text format with reference to 
GRADE evidence tables (see Table 7-1). 
 
Datenextraktion  
und Bewertung des 
Bias-Risikos laut  
IHE Checkliste 
Evidenzsynthese  
mittels GRADE 
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3 Description and technical 
characteristics of technology 
Features of the technology and comparators 
B0001 – What is 177Lu-PSMA and the comparators? 
177Lu-PSMA and labelling 
177 Lutetium (177Lu) is, to date, the most widely used radioisotope for tar-
geted therapy in prostate cancer (PC). In terms of its properties, it is a me-
dium energy β-emitter (490 KeV) with a maximum energy of 0.5 MeV and a 
maximal tissue penetration of <2 mm [9]. 177Lu is a reactor produced radio-
metal that emits low-energy γ‐rays at 208 and 113 keV with 10 and 6% abun-
dance, respectively [9]. It has a relatively long physical half-life of 6.73 days, 
which, together with the properties above, makes it a favourable theranostic 
agent [9]. Administration of a single dose ranges from 3-9.3GBq [9]. 
Prostate specific membrane antigen (PSMA) is a target for radionuclide ther-
apy of PC and its metastases [24]. PSMA, known also as Glutamate Carbox-
ypeptidase II (GCPII, EC 3.4.17.21), N-acetyl-┙-linked acidic dipeptidase I 
(NAALADase), or folate hydrolase, is a 750 amino acid type II transmem-
brane glycoprotein that is thought to have a number of functions with rela-
tion to nutrient uptake, cell migration, cell survival, and cell proliferation [25]. 
Under normal conditions, PSMA is expressed at low levels in prostate epi-
thelium, but in the majority of PC patients (in more than 90%), it is overex-
pressed up to 1,000 times [8]. PSMA, however, is not only prostate specific, 
but it is also expressed in other cells found, for instance, on kidneys, liver, 
spleen, bone marrow, salivary, lacrimal, and parotid glands [9]. Because of 
the correlation between PSMA expression and the Gleason score (used for 
staging of PC) [18], PSMA is considered to be a valid prognostic and diag-
nostic biomarker [19]. 
Labelling of cells can be done in various ways using different PSMA peptides 
and antibodies [9]. Because the PSMA receptor has an internalization pro-
cess allowing endocytosis of bound proteins on the cell surface into an endo-
somal compartment, PSMA labelled radioisotopes like 177Lu can be concen-
trated within the cell [26]. In the studies included in this assessment, the dif-
ferent types of labelling include three ways of chemical conjugation of a pep-
tide, thus three studies used 177Lu-PSMA-DKFZ-617 [10-12], one study used 
177Lu-PSMA-I&T [13], and the other 177Lu-PSMA-617 [14]. 
Comparators 
The role of 177Lu-PSMA in the care pathways of PC patients is partly un-
clear. While all the studies included in the analysis use 177Lu-PSMA as an 
experimental intervention after the exhaustion of all therapeutic options (see 
the Table A-1), the German AWMF S3 guideline includes 177Lu-PSMA in 
the category of second line therapies for metastatic castration-resistant pros-
tate cancer (mCRPC) [22].  
If 177Lu-PSMA is understood as a second line therapy, hormonal therapies 
with abiraterone (alone or in combination with prednisone) or enzalutamide 
are considered as alternatives. Both of these hormonal therapy interventions 
are indicated after progression of PC despite the first line androgen depriva-
tion therapy [3]. Abiraterone inhibits the products of CYP17 gene and in do-
177LU ist das  
am häufigsten 
verwendetste 
Radioisotop im Bereich 
der zielgerichteten 
Therapie von 
Prostatakarzinomen 
PSMA = molekulares 
Target für die 
Radionuklidtherapie  
kennzeichnen  
von Zellen mittels 
verschiedener PSMA 
Peptide und Antikörper  
unklare Einordnung in 
den Therapiealgorithmus 
des Prostatakarzinoms 
als Zweitlinientherapie 
wäre 177Lu-PSMA eine 
mögliche Alternative zur 
Hormontherapie (Abira-
terone, Enzalutamide) 
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ing so, it blocks the synthesis of androgens in the tumour as well as in the 
testis and adrenal glands [3]. Enzalutamide acts in multiple sites in the an-
drogen receptor signalling pathway and unlike in abiraterone, concurrent 
treatment with steroids is not required [3]. 
An alternative to the above hormonal therapy, chemotherapy options include 
docetaxel (with prednisone), cabazitaxel, mitoxantrone, and estramustine. 
While estramustine is an estrogen and cytostatic antineoplastic agent com-
bined, the former three agents all belong to the class of anticancer agents 
called taxanes that bind to and stabilize microtubules causing cell-cycle ar-
rest and apoptosis [3].  
Further comparators to 177Lu-PSMA are immunotherapy options including 
sipuleucel-T that is a dendritic cell vaccine prepared from peripheral blood 
mononuclear cells obtained by leukapheresis where the activated cells are in-
fused back into the patients ca three days after harvesting [3]. Sipuleucel-T 
is, however, not accessible in Europe. Radiopharmaceuticals like Radium 223 
are also an alternative as they allow for deposition of high-energy radiation 
over a shorter distance than it is the case with beta-emitting radioisotopes, 
thus minimizing toxicity [3]. Steroids like dexamethasone, prednisolone, 
prednisone represent the last set of alternatives that can be prescribed alone, 
or in combination with the set of therapy options outlined above mainly for 
the sake of symptom and side-effect management [22]. 
A0020 – For which indications has 177Lu-PSMA received  
marketing authorisation or CE marking? 
As indicated by the manufacturer Scintomics, 177Lu-PSMA has neither CE 
mark, nor FDA approval. The therapy is currently performed either under 
clinical trials or under local regulations for unproven interventions for pa-
tients who have exhausted all therapeutic options [20]. Since 2019, 177Lu-
PSMA is part of the German DRG system [21]. 
B0002 – What is the claimed benefit of 177Lu-PSMA in relation  
to the comparators? 
The main claimed benefit is that 177Lu-PSMA offers an extra therapeutic 
option for mCRPC patients in the end stage of cancer. Through its targeted 
approach, 177Lu-PSMA claims to reduce the level of prostate specific anti-
gen (PSA), have potential survival benefits with respect to progression free 
survival as well as overall survival, and have a safe profile that causes a min-
imal number of grade 3-4 toxicities [15]. 
B0003 – What is the phase of development and implementation  
of 177Lu-PSMA and the comparators? 
At this point in time, the manufacturer Endocyte® is in the process of applying 
for an FDA approval with their ongoing randomized controlled trial (RCT) 
comparing 177Lu-PSMA to best standard care (NCT03511664). So far, there 
were five prospective trials published by 2018 and no controlled trials pub-
lished on 177Lu-PSMA for mCRPC. One further RCT (NCT03392428) com-
paring 177Lu-PSMA to the chemotherapy cabazitaxel is also in the recruit-
ing phase. Moreover, the question of individual patient dosimetry is still a 
matter research [19]. 
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Administration, Investments, personnel and tools  
required to use 177Lu-PSMA and the comparators 
B0004 – Who administers 177Lu-PSMA and the comparators and  
in what context and level of care are they provided? 
B0008 – What kind of special premises are needed to use 177Lu-PSMA 
and the comparators? 
According to the questionnaire from the submitting hospital, 24 hour clinical 
observation and gamma camera imaging is preferable with patient’s maxi-
mum stay of two days. The studies included for the analysis were conducted 
in the inpatient setting where 2-4 days of post-intervention observation was 
reported in one study [13]. Depending on the context, the Australian regula-
tion allows for 177Lu-PSMA to be administered in the outpatient setting, the 
German regulation requires a minimum three day hospital admission [9], 
and the Austrian Radiation-protection guideline (Strahlenschutz-Richtlini-
en) allows for 177Lu-PSMA to be performed both in outpatient as well as 
inpatient context. 
177Lu-PSMA is administered in secondary and tertiary levels of care in the 
hospital’s radiology department either as a slow injection by hand, or via an 
infusion pump [20]. According to the submitting hospital, experts in nuclear 
medicine, radiology technology, and medical physics are necessary. Further-
more, the intervention is to be performed in 3-4 cycles at intervals of 6-8 
weeks that may be interrupted according to pre-defined criteria such as PSA 
increase after two cycles. 
The inpatient or outpatient administration of the alternative second line treat-
ment depends on the specific intervention. While hormonal therapy and ster-
oids can be administered in an oral form in the outpatient or home context, 
immunotherapy, radiotherapy, and chemotherapy are predominantly admin-
istered in the inpatient setting. 
No special premises are required for the administration of 177Lu-PSMA as 
well as the alternative treatment options. According to the submitting hospi-
tal, the only premises and equipment required for the administration of 177-
Lu-PSMA are warm room, C lab equipment, and gamma camera. 
B0009 – What supplies are needed to use 177Lu-PSMA  
and the comparators? 
177Lu-PSMA can be either purchased from the manufacturers listed (Endo-
cyte®, Scintomics GmbH, Telix Pharmaceuticals Limited), or prepared by in-
dividual radiopharmacists. On top of the intervention itself, a single day kid-
ney protection protocol may be followed, which includes a cocktail of lysine 
and arginine diluted in two litres of normal saline infused over four hours, 
starting 30–60 min before the 177Lu-PSMA infusion [11]. 
Furthermore, depending on the patient’s health state before the intervention, 
application of the following agents may be considered: diuretics in cases of 
urinary flow disorders; laxatives in cases of constipation to support rapid 
clearance of unbound 177Lu-PSMA; icepacks for the salivary glands to po-
tentially reduce blood flow and 177Lu-PSMA uptake during the blood pool 
phase until approximately four hours after the start of radio ligand therapy; 
prophylactic antiemetic therapy such as ondansetron; and corticosteroids in 
cases of cerebral, spinal, or other metastases with risk of swelling and me-
chanical obstruction [20]. 
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Concerning supplies for the comparators of hormonal therapies, chemother-
apy, immunotherapy, radiopharmaceuticals, and steroids, what is needed are 
the specific substances together with potential interventions for the treatment 
of comorbidities. 
 
Regulatory & reimbursement status  
A0021 – What is the reimbursement status of 177Lu-PSMA? 
Up until the end of 2018, 177Lu-PSMA was performed under either clinical 
trials or under local regulations for unproven interventions for patients who 
have exhausted all therapeutic options [20]. Since 2019, 177Lu-PSMA is in-
cluded in the German DRG system [21]. 
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aufgenommen 
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4 Health Problem and Current Use 
Overview of the disease or health condition 
A0001 – For which health conditions, and for what purposes  
is 177Lu-PSMA used? 
A0002 – What is the disease or health condition in the scope  
of this assessment?  
177Lu-PMSA is used as the last line of treatment of metastatic castration-
resistant prostate cancer (mCRPC). The growth of PC is driven by male sex 
hormones called androgens. Hence, the common first line treatment option 
is to lower their level in the man’s body androgen deprivation therapy (ADT) 
[27]. Even though 80-90% of patients respond to androgen therapy, nearly 
all eventually develop progressive CRPC [2], which can be measured by the 
rise in PSA levels, progression of existing metastases, or the presence of new 
metastases [4]. The exact number of mCRPC patients is unclear as there are 
no widely accepted criteria for its definition outside of the clinical trial set-
ting [3]. Once the only evidence is the rise of PSA levels, whether it is the in-
stance of CRPC is particularly unclear because the decision requires judg-
ment on the part of the treating physician. While some define CRPC by a 
serum PSA rising over one month to more than two ng/mL, others define it 
by PSA twofold rise [3]. Gleason Score is the tool used for determining the 
aggressiveness of prostate cancer [28]. 
A0003 – What are the known risk factors for mCRPC? 
With 1.4 million cases in 2016 globally, PC is the most common incident 
cancer for men [1]. The risk of prostate cancer in the US men is one in six 
[29], but the rates differ over 50-fold among various world populations with 
Western countries leading the incidence rate [5]. One of the factors is ethnic-
ity as PC is more common in black than white and Hispanic men, and least 
common in Asian [5, 6]. 
The incidence also increases proportionally with age as in the Western coun-
tries, the incidence is ~12% in the 60-69 year old men, whereas it is ~48% 
in 80-89 year old [6]. Furthermore, genetic factors, diet, cigarette smoking, 
hormone levels, and obesity also play a role [5]. 
A0004 What is the natural course of mCRPC? 
The natural course of PC is primarily dependent on tumour aggressiveness. 
PC can remain silent throughout a man’s life without being detected [7], es-
pecially in the context of the proportional increase in the incidence of PC 
with age [6]. However, if PC grows to the stage of producing symptoms like 
bladder neck obstruction, invasion of adjacent organs, or distant metastasis, 
curative treatment is usually impossible [7]. For that reason, PSA blood tests 
have been used for screening of PC, but amidst controversies about their sur-
vival benefit and the question of overdiagnosis, PSA screening is currently not 
recommended, for instance by USPSTF or by Public Health England [30]. 
Because nearly all patients who initially respond to ADT eventually develop 
mCRPC, the natural course of mCRPC is death [2]. Bone metastases occur 
in 90% of men with mCRPC and can produce significant morbidity such as 
pain, pathologic fractures, spinal cord compression, and bone marrow failure. 
Paraneoplastic effects are also common, including anaemia, weight loss, fa-
tigue, hypercoagulability, and increased susceptibility to infection [31]. 
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Effects of the disease or health condition  
on the individual and society 
A0005 – What is the burden of disease for patients with mCRPC? 
According to Global Burden of Disease 2015, global estimates of the age stand-
ardized death rate for PC are 14.24 deaths (95% CI: 11.8-17.95) per 100,000 
person-years [32]. While the prostate cancer mortality rate is decreasing in 
high income countries, the incidence and burden of disease is steadily in-
creasing globally [32]. In 2016, PC was the cancer with the highest incidence 
for men in 92 countries, and the leading cause of cancer deaths for men in 48 
countries [1]. The increasing incidence rates, together with an ageing and 
growing population, have led to a 40% increase in prostate cancer cases be-
tween 2006 and 2016 [1].  
According to Statistik Austria, the mortality from PC in 2016 was 1,225 with 
the highest mortality in the states with highest incidence rates of Lower Aus-
tria, Upper Austria, and Vienna [33]. 
A0006 – What are the consequences of mCRPC for the society? 
The consequences of PC for the society lie not only in the costs related to the 
pharmacological treatment, but also in the costs from a societal perspective 
that are present when PC impedes on a person’s life, particularly on work 
activity. Globally in 2016, PC caused 6.1 million (95% UI, 5.0-6.6 million) 
disability-adjusted life years (DALYs) with 91% coming from years of life 
lost and 9% from years lived with disability [1]. 
 
Current clinical management of the disease or health condition 
A0024 – How is mCRPC currently diagnosed according  
to published guidelines and in practice? 
PC is either found via screening for PSA or via the occurrence of symptoms 
in more advanced cancers. PC screening, as mentioned in A0004, however, is 
one of the most controversial topics in current urology as three large pro-
spective RCTs result in conflicting positions [34]. 
According to the European Association of Urology (EAU), PC is usually sus-
pected on the basis of digital rectal exam (DRE) and/or PSA levels [34]. In 
~18% of cases, PC is detected by suspect DRE alone, irrespective of PSA 
levels [34]. Yet, as an independent variable, PSA is a better predictor of can-
cer than DRE [34]. Definitive diagnosis, however, depends on histopatholog-
ical verification of adenocarcinoma in prostate biopsy cores or specimens from 
transurethral resection of the prostate (TURP) or prostatectomy for benign 
prostatic enlargement (BPE).  
Ultrasound-guided biopsy is the current standard of care with prostate biop-
sy being performed by either the transrectal or transperineal approach [34]. 
Biopsy may then show prostate cancer, precancerous, or benign findings. If 
the biopsy indicates prostate cancer, architectural features of the cells in the 
biopsy tissue are used to generate a Gleason grade that correlates closely with 
clinical behaviour [35]. The Gleason grade is key to determining treatment 
approaches [35]. Repeated biopsy may be indicated, for instance, in situa-
tions when PSA level increases further or if findings on digital rectal exami-
nation or prostate imaging warrant rebiopsy [35]. 
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In situation when PC initially presents after becoming metastatic to bone, 
pain is the most common manifestation [36]. The choice of imaging proce-
dure is guided by the clinical setting and includes: radionuclide bone scan, 
plain radiographs, and magnetic resonance imaging [36]. 
A0025 – How mCRPC currently managed according  
to published guidelines and in practice? 
In localized PC, a life expectancy of at least 10 years is considered mandato-
ry for any benefit from local treatment [34]. Comorbidity is more important 
than age in predicting life expectancy in men with PC [34]. However, for those 
men with a short life expectancy, watchful waiting with symptom-guided 
treatment is appropriate in order to maintain quality of life [34]. Radical 
prostatectomy is in place only if the goal is eradication of PC, while, when-
ever possible, preserving continence and potency is important [34]. 
Concerning mCRPC patients, ADT is the first line therapy and it can be ac-
complished either with bilateral orchiectomy (surgical castration) or medical 
orchiectomy [3]. Currently, multiple agents are given in conjunction with 
continued ADT or as a second line therapy, which, according to the German 
AWMF S3 guideline, include (the selection of comparators listed in B0001) 
[22]: 
 Interference with androgenic stimulation of prostate cancer growth 
through abiraterone or enzalutamide.  
 Taxane chemotherapy using docetaxel, cabazitaxel, mitoxantrone, or 
estramustine. Docetaxel (with prednisone) is the standard therapy reg-
imen and cebazitaxel is the option of choice for patients who progress 
despite using docetaxel, yet at the same time for those who show that it 
prolonged their survival. Mitoxantrone is an added therapeutic option 
as both of the taxanes above have shown superiority to mitoxantrone [3]. 
 Immunotherapy via the use of sipuleucel-T. 
 The bone-targeted radiopharmaceutical therapy with Radium-223. 
 Steroids such as dexamethasone, prednisolone, and prednisone. 
The above approaches have in general not been compared with each other in 
a large RCT. The proper sequencing of these approaches requires considera-
tion of multiple factors, in particular, the sites and extent of disease involve-
ment and the rate of disease progression. Both hormonal as well as chemo-
therapy treatment options, however, are effective only temporarily and pa-
tients can develop resistance [15]. 
 
Target population 
A0007 – What is the target population in this assessment? 
A0023 – How many people belong to the target population?  
The target population of this assessment are mCRPC patients of more than 
18 years of age who have exhausted all therapeutic options and have an ex-
pression of PSMA as conventionally measured by 68Ga-PSMA- PET CT. 
According to Statistik Austria, the annual number of disseminated PC (most 
presumably an equivalent to mCRPC) is 242.3 patients [33]. Furthermore, 
the annual PC incidence rate in 2016 in Austria was 5,245 with the highest 
incident rate in Lower Austria, Upper Austria, and Vienna [33]. For the com-
parison, the age-standardized incidence rate from the European Standard 
Population in 2016 was 138.3 per 100,000 men per year [33]. 
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A0011 – How much is 177Lu-PSMA utilised? 
The previous administrations of 177Lu-PSMA in mCRPC patients have been 
within the scope of clinical trials or under local regulations for unproven 
interventions for patients who have exhausted all therapeutic options [20]. 
The German University Clinics offer radio ligand therapies since 2013 on a 
compassionate use basis and they developed a consensus recommendation on 
the use of 177Lu-PSMA [37, 38]. Because neither the manufacturers, nor the 
submitting hospital have answered the question on the volume of utilization, 
an estimate on the number of current and potential/expected utilisation of 
177Lu-PMSA is not yet available for Austria. 
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5 Clinical effectiveness 
5.1 Outcomes 
The following outcomes were defined as crucial to derive a recommendation: 
 Overall survival (OS)  
 Quality of Life (QoL)  
 Health Related Quality of Life (HRQoL)  
The following outcomes were defined as surrogate to derive a recommendation: 
 Progression free survival (PFS) 
 Response evaluation criteria in solid tumours (RECIST)  
 Prostate Specific Antigen (PSA) PFS  
Concerning crucial outcomes, the outcome OS (reported in the form of a me-
dian) refers to the amount of time after which 50% of the patients have died 
and 50% have survived. For the outcome of QoL that measures aspects of an 
individual’s sense of well-being and ability to carry out activities of daily liv-
ing, Eastern Cooperative Oncology Group (ECOG), Karnofsky Performance 
Status (KPS), and European Organisation for Research and Treatment of 
Cancer (EORTC-Q30) were included. Furthermore, the following pain scores 
were included as a sub-outcome of QoL: Visual Analogue scale (VAS) and 
Brief Pain Inventory Short-Form (BPI-SF). Also, the outcome HRQoL that 
measures aspects of an individual’s sense of well-being with respect to phys-
ical and mental health in connection to prostate cancer that was included 
was Functional Assessment of Cancer Therapy – Prostate cancer (FACT-P). 
Concerning surrogate outcomes, PFS refers to progression free survival con-
firmed radiographically (PET/CT/MRI/SPECT scans) or otherwise. The 
outcome RECIST response refers to a method measuring patients’ response 
to treatment: when tumours improve (“respond”), stay the same (“stabilize”), 
or worsen (“progress”) during treatment. And, PSA PFS refers to PFS as 
measured by the PSA levels.  
 
 
5.2 Included studies 
Study characteristics and results of included studies are displayed in Table 
A-1 and in the evidence profile in Table 7-1. 
No study fulfilled the study inclusion criteria for assessing clinical effective-
ness of the 177Lu-PSMA. RCTs and non-randomised CTs were considered 
for inclusion, but could not be identified through the systematic literature 
search (see Figure 2-1). 
Observational evidence consisting of five prospective before-after studies was 
included [10-14] and is described in the results on safety. 
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5.3 Results 
Mortality 
D0001 – What is the expected beneficial effect of 177Lu-PSMA  
on mortality? 
No evidence was found to answer the research question. 
D0003 – What is the effect of 177Lu-PSMA on the mortality  
due to causes other than mCRPC? 
No evidence was found to answer the research question. 
 
Morbidity 
D0005 – How does 177Lu-PSMA affect symptoms and findings  
(severity, frequency) of mCRPC? 
No evidence was found to answer the research question. 
D0006 – How does 177Lu-PSMA affect progression (or recurrence)  
of mCRPC? 
No evidence was found to answer the research question. 
 
Function 
D0011 – What is the effect of 177Lu-PSMA on patients’ body functions? 
No evidence was found to answer the research question. 
D0016 – How does the use of 177Lu-PSMA affect activities of daily living? 
No evidence was found to answer the research question. 
 
Health-related quality of life 
D0012 – What is the effect of 177Lu-PSMA on  
generic health-related quality of life? 
No evidence was found to answer the research question. 
D0013 – What is the effect of 177Lu-PSMA on  
disease-specific quality of life? 
No evidence was found to answer the research question. 
 
Patient satisfaction 
D0017 – Was the use of 177Lu-PSMA worthwhile? 
No evidence was found to answer the research question. 
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6 Safety 
6.1 Outcomes 
The following outcomes were defined as crucial to derive a recommendation: 
 Serious adverse event (SAEs) 
Additional outcomes considered were Adverse event (AEs): 
 All grade 3-4 toxicities  
 Discontinuation rate 
Concerning crucial outcomes, SAEs included were study related death.  
Additional outcomes considered were all grade 3-4 toxicities related to treat-
ment such as nephrotoxicity, hematotoxicity, hepatotoxicity, and bone pain 
flare, as measured by Common Terminology Criteria for Adverse Events 
(CTCAE) version 5.0. Discontinuation rate, referring to the rate at which cli-
nicians or patients themselves discontinued the treatment, was also consid-
ered.  
 
 
6.2 Included Studies 
The study inclusion criteria for assessing safety differed from the ones for as-
sessing clinical effectiveness. In addition to RCTs and non-randomised CTs, 
prospective studies without a control group were considered for the assess-
ment of safety. The systematic literature search (see Figure 2-1) identified 
five prospective before-after studies that matched our inclusion criteria [10-
14]. 
Study characteristics and results of included studies are displayed in Table 
A-1 and in the evidence profile in Table 7-1. 
 
Study characteristics 
Four studies were explicitly conducted in one centre [11-14], but it was un-
clear in the fifth [10]. Countries of recruitment were Germany [13], Austral-
ia [10, 12], Austria [14], and India [11]. Study recruitment times were either 
not stated [10, 14], or in the rest of the studies, they were between 05/2013 – 
12/2016 [11-13]. Clinical follow-up was unclear in two studies [10, 14], and 
ranged from mean 13 to median 25 months in the remaining 3 studies [11-
13]. Loss to follow-up was 35.7% in one study [10], and it was unclear or un-
reported in the remaining studies [11-14]. None of the studies was explicitly 
sponsored by the any of the manufacturers, but a member of the authoring 
team in one study was a shareholder at Scintomics, Germany [13]. One study 
had no funding [11], another study was funded by Peter MacCallum Foun-
dation and Prostate Cancer Foundation [12], another by University of Inns-
bruck and Medical University of Innsbruck [14], and the last by Paul Ramsey 
Foundation [10].  
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In terms of the chemical conjugation of the labelled peptide, three studies 
used 177Lu-PSMA-DKFZ-617 [10-12], one study used 177Lu-PSMA-I&T [13], 
and the other 177Lu-PSMA-617 [14]. The mean strength of radiation ranged 
in all studies from 5.07 (SD±1.85) to 7.5 (range 4.4-8.7) and the average num-
ber of cycles per patient ranged from 2.2 to 3.2 [10-14]. In terms of imaging 
procedures, all studies used PET/CT with 68Ga-PSMA for selection of pa-
tients and therapy monitoring [10-14]. Two studies also used 18F-FDG PET/ 
CT, bone scan, and CT of the chest, abdomen, and pelvis [10, 12]. 
 
Patient characteristics  
Overall, out of the total of 141 patients included in the five studies, basic 
characteristics were reported on 116 patients. In terms of inclusion criteria, 
PSMA expression and exhaustion of all therapeutic options were the condi-
tions in all studies [10-14], whereas two studies also specified that patients 
should have had ECOG less or equal to two, life expectancy of more than 12 
weeks, and confirmed disease progression [10, 12]. One of them also required 
specific baseline blood counts [10]. 
In terms of exclusion, two studies did not state their exclusion criteria [13, 
14], two studies further excluded patient with clinically significant impaired 
bone marrow [10, 12], two studies excluded patients with specific poor base-
line blood counts [11, 12], of which one also excluded patients with clinically 
significant impaired kidney and liver function, and patients who used con-
comitant nephrotoxic drugs, who had radiotherapy within six weeks, or who 
had uncontrolled intercurrent illness [12]. 
Concerning the use of co-interventions, two studies allowed the concomitant 
use of denosumab or biphosphorate [10, 12], whereas one of them also al-
lowed the use of blood transfusions, palliative radiotherapy, and 2nd genera-
tion anti-androgens [12] and the other allowed the use of luteinising hormone-
releasing hormone (LHRH) agents [10]. One other study also applied the use 
of a kidney protection cocktail of lysine and arginine diluted in two litres of 
normal saline before the application of 177Lu-PSMA [11]. 
With regards to prior treatments, hormone therapy was used in two studies 
[11, 13], LHRH therapy in three [10, 13, 14], external beam radiation as well 
as surgical therapy in three [11, 13, 14], chemotherapy was used in all stud-
ies [10-14], and antiandrogens and bone interventions in four [10, 12-14].  
Concerning further baseline criteria, the median age in four studies ranged 
from 67 (range 56-82) to 72 (range 50-88) [10, 12-14], with one stated as a 
mean of 65.9 (range 38-81) [11]. Baseline median Gleason score ranged from 
eight to nine in three studies [10, 12, 13], it was more or equal to eight with-
out stating the statistical measure in one study [14], and unclearly reported 
in another [11]. Baseline ECOG performance status was not reported in two 
studies [13, 14], it was reported as a mean of 2.54 in one study [11], and it 
was reported in categories 0/1/2 in two studies with 37/47/17% of patients in 
one of them [12], and 35.7/64.3/0.0% of patients in each category in the other 
[10]. Tumour stage was explicitly reported in one study with tumour stages 
1/2/3/4 in 13/23.2/62.5/12.5% of patients, respectively [13]. Baseline toxicity 
was reported in one study with 32.3% of patients having grade 1 haemoglobin 
toxicity [11]. 
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6.3 Results 
Patient safety 
C0008 – How safe is 177Lu-PSMA in comparison to the comparators? 
In the absence of data from CTs, no comparisons can made between the 177-
Lu-PSMA and the comparators. Only intervention related complications can 
be considered for the analysis of safety because the effects directly attributa-
ble to the intervention can be analysed without a control group. 
Concerning SAEs, the outcome of study related death was reported in two 
studies and it did not occur in either [12, 13]. 
Concerning AEs, the outcomes of discontinuation rate was reported in one 
study where no patients discontinued treatment [12]. With respect to grade 
3-4 toxicities, nephrotoxicity was reported in four studies, but did not occur 
either [11-14]. With respect to hematotoxicity: lymphocytopenia was reported 
in three studies [12-14] and occurred in one in 37% of patients [12], throm-
bocytopenia and anaemia were both reported in four studies [10, 12-14] and 
both occurred in one in 13% of patients [12], neutropenia was reported in 
three studies [12-14] and occurred in one in 7% of patients [12], and haemo-
globin toxicity was reported in one study in 3.2% of patients [11]. Hepato-
toxicity was reported in two studies, but did not occur in either [11, 14], while 
bone pain flare was reported in one study and occurred in 3% of patients [12]. 
C0002 – Are the harms related to dosage or frequency  
of applying 177Lu-PSMA? 
As 177Lu-PSMA is a therapy that targets the specific antigen expressed on 
the surface of PC tumour cells as well as on other cells such as kidneys, liver, 
spleen, bone marrow, salivary, lacrimal, and parotid glands, the precision of 
177Lu-PSMA therapy is important. There is no agreement on which of the 
above organs is the main dose limiting one and hence which one is most sus-
ceptible to harms related dosage of 177Lu-PSMA [15-19]. Furthermore, it was 
observed that treatment outcome is worse in patients with organ metastases 
and elevated lactate dehydrogenase in blood tests [39]. For these reasons, in-
dividual patient specific dosimetry presents key challenges as on the one hand, 
the goal is to apply maximal justifiable dose of 177Lu-PSMA that does not 
cause serious toxicity in order to get the antitumor effect and on the other 
hand, if radiation gets to be absorbed by bone marrow, fatal damage is pos-
sible [40]. In this respect, a possible harm was reported in one study where a 
significant bone pain during the administration of 177Lu-PSMA occurred in 
7.1% of patients (n=1/14) [10]. Furthermore, there are harms related to the 
frequent use of computed tomography (CT) scans as those have an impact on 
mCRPC patients’ morbidity [41]. 
C0004 – How does the frequency or severity  
of harms change over time or in different settings? 
As 177Lu-PSMA is the last intervention used after the exhaustion of all ther-
apeutic options, the patient population at stake has received a list of previ-
ous interventions beforehand, which makes it hard to directly attribute any 
effect to 177Lu-PSMA. Also, there is no data with longer term follow-up than 
median 25 months (IQR 12.7-25.2) from one study [12] where the highest 
number of AEs are reported. However, it remains unclear at what time-point 
the safety data were reported and hence no conclusions can be made about 
the change in frequency or severity of harms over time. 
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Also, there is no data concerning the delivery of 177Lu-PSMA in other than 
inpatient setting and hence, even though 177Lu-PSMA could in theory be al-
so used in the outpatient context in Austria (according to the questionnaire 
from the submitting hospital), there is no data comparing the safety profile of 
the 177Lu-PSMA use in the two settings. 
C0005 – What are the susceptible patient groups  
that are more likely to be harmed through the use of 177Lu-PSMA? 
The most susceptible patient groups are patients with low baseline QoL and 
patients with comorbidities – especially those with comorbidities related to 
the dose limiting organs of kidneys, liver, spleen, bone marrow, salivary, lac-
rimal, and parotid glands [15-18]. 
C0007 – Are 177Lu-PSMA and comparators associated  
with user-dependent harms? 
No information was found to answer this research question.  
 
Investments and tools required 
B0010 – What kind of data/records and/or registry is needed  
to monitor the use of 177Lu-PSMA and the comparators? 
RCT data are needed to establish the efficacy of 177Lu-PSMA and prospec-
tive registry data to monitor its use for the sake of providing a longer-term 
safety and efficacy follow-up data. 
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geringe Lebensqualität 
und Komorbiditäten 
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Wirksamkeitsdaten  
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7 Quality of evidence 
The risk of bias (RoB) for individual studies was assessed with the Institute 
of Health Economics (IHE) checklist for single-arm studies (CITE) and it 
is presented in Table A-2 in the Appendix [42]. The overall RoB ranged from 
low to high, with two studies being ranked as high [13, 14], two studies as me-
dium [10, 11], and one as low [12]. The main reasons for downgrading were 
lack of clarity concerning consecutiveness of recruitment, eligibility criteria, 
and patients’ stage of disease when entering the study. Also, studies were 
downgraded due to no reporting of co-interventions, length and loss to follow 
up, and due to no blinding.  
The strength of evidence was rated according to GRADE (Grading of Recom-
mendations Assessment, Development and Evaluation) Schema [23] for each 
endpoint individually. Each study was rated by three independent research-
ers. All disagreements were resolved among the researchers. A more detailed 
list of criteria applied can be found in the recommendations of the GRADE 
Working Group [23].  
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close  
to that of the estimate of the effect;  
 Moderate = We are moderately confident in the effect estimate: the 
true effect is likely to be close to the estimate of the effect, but there 
is a possibility that it is substantially different;  
 Low = Our confidence in the effect estimate is limited: the true effect 
may be substantially different from the estimate of the effect;  
 Very low = Evidence either is unavailable or does not permit  
a conclusion. 
The ranking according to the GRADE scheme for the research question can 
be found in the evidence profile table below (see Table 7-1). 
Overall, the strength of evidence for clinical effectiveness was not assessed 
due to the lack of controlled studies as no evidence was available comparing 
177Lu-PSMA and any second line therapy (or higher line therapy) or best 
supportive care. Regarding safety of 177Lu-PSMA, the quality of evidence 
was low (for outcomes of SAEs and discontinuation rate) – due to the study 
design, and very low (for the outcome of grade 3-4 toxicities) – due to RoB 
and inconsistency in reporting on the outcome of grade 3-4 toxicities. 
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Table 7-1: Evidence profile: efficacy and safety of 177Lu-PSMA in mCRPC patients 
Certainty assessment 
Estimate of effect Certainty Importance № of 
studies 
Study  
design 
Risk  
of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
Efficacy 
Due to the lack of a controlled group, no data on efficacy can be reported. 
Safety 
Serious adverse events 
2 (55 pts) prospective 
before-after 
studies  
not serious not serious  not serious  not serious  none  SAEs occurred in 0/55 pts and were not reported  
in the remaining 55 pts 
⨁⨁◯◯ 
LOW 
CRITICAL 
Adverse events 
Grade 3-4 toxicities 
5 (116 pts) prospective 
before-after 
studies 
serious a serious b not serious  not serious  none  nephrotoxicity occurred in 0/96 pts,  
hematotoxicity occurred in 11/65 pts,  
thrombocytopenia and anemia occurred in 4/79 pts,  
neutropenia occurred in 2/65 pts,  
hemoglobin toxicity occurred in 1/31 pts,  
hepatotoxicity occurred in 0/41 pts,  
bone pain flare occurred in 1/30 pts 
⨁◯◯◯ 
VERY LOW 
CRITICAL 
Discontinuation rate 
1 (30 pts) prospective 
before-after 
study 
not serious not serious not serious  not serious  none  no discontinuation rate was reported in 80 pts and 
0/30 pts discontinued therapy in Hofman et al. 
⨁⨁◯◯ 
LOW 
IMPORTANT 
 
Abbreviations: IHE = Institute of Health Economics, RoB = risk of bias, pts = patients 
Explanations 
a Using the IHE RoB checklist, 2 studies were evaluated to have high, 2 medium, and 2 low risk of bias. 
b The study with the lowest risk of bias reports grade 3-4 toxicities occurring in up to 37% of patients while the remaining studies report no toxicities. 
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8 Discussion 
To our knowledge, this is the first systematic review (SR) of 177Lu-PSMA for 
mCRPC patients that is based on prospective evidence only. In our system-
atic search, there were three SRs found that all included both prospective as 
well as retrospective studies and were published in 2017 and 2018. All three 
SRs conclude a positive efficacy as well as safety profile of 177Lu-PSMA based 
on the outcome of PSA decline and SAEs/AEs [43-45].  
 
Summary of evidence from prospective clinical studies 
We found no controlled trials for the analysis of clinical effectiveness. For 
the analysis of safety, we found five prospective before-after studies includ-
ing 141 patients receiving 177Lu-PSMA. 
Intervention related complications based on the prospective observational 
studies without a control group suggest that 177Lu-PSMA was not related to 
any SAEs in the form of study related death. Furthermore, with respect to 
AEs of grade 3-4 toxicities, 177Lu-PSMA was not related to any nephrotoxi-
city and hepatotoxicity, but it was related to bone pain flare and a list of hem-
atotoxicities reported in one study [12]: lymphocytopenia in 37% of patients, 
thrombocytopenia and anaemia in 13% of patients, neutropenia in 7% of pa-
tients, and haemoglobin toxicity reported in another study in 3.2% of patients 
[11]. Regarding the AE of discontinuation rate, it was reported in one study 
where no patients discontinued treatment [12]. 
 
Internal and external validity 
Overall, the strength of evidence for clinical effectiveness was not assessed 
due to the lack of controlled studies. Regarding safety of 177Lu-PSMA, the 
quality of evidence was low (for outcomes of SAEs and discontinuation rate) 
to very low (for the outcome of grade 3-4 toxicities). 
Challenges with interpreting the data arise when we take into consideration 
the extent to which the patient population was pre-treated before the admin-
istration of 177Lu-PSMA, where previous interventions include hormone ther-
apy, LHRH agents, external beam radiation, surgical therapy, chemotherapy, 
antiandrogens, and bone interventions. Hence, in the light of the lack of con-
trolled data, assigning the effects observed to 177Lu-PSMA is questionable. 
Also, interpreting the data is especially problematic in the light of only one 
study reporting on the baseline toxicity data [11] and only two studies report-
ing on the co-interventions that patients continued on during the course of 
177Lu-PSMA, which ranged from blood transfusions to bone interventions, 
palliative radiotherapy, anti-androgens, and LHRH agents [10, 12]. Further-
more, it remains unclear why all reported instances of AEs – except for hae-
moglobin toxicity [11] – occurred in only one study that acknowledged the 
co-interventions used, had the best standard of reporting, longest follow-up, 
and the lowest RoB [12]. 
In terms of external validity, the data is considered generalizable to the Aus-
trian context as the countries of recruitment were Germany, Australia, Aus-
tria, and India. At the same time, however, as the Austrian context allows for 
the administration of 177Lu-PSMA also in the outpatient setting, none of the 
studies included reported data from this context and hence in this respect, 
no conclusions can be made.  
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Effectiveness data from observational studies 
With respect to crucial outcomes, the data from the five observational studies 
with 141 patients suggest the following. Median OS was not reached in one 
study at 15.5 months follow-up [13], in another study, it was 13.5 months 
(95% CI: 10.4-22.7) [12], in another 16 months [11], and reported as a mean, 
it was 12.5 months (SD ± 33 weeks) in the last study [10].  
QoL was reported using the EORTC-QLQ-C30 score in one study, where the 
mean difference in score after three months post last 177Lu-PSMA cycle com-
pared to baseline was 0 points [12]. QoL was also reported in another study 
using KPS and ECOG scores that were reported as mean score three months 
after the last 177Lu-PSMA cycle compared to baseline. KPS scores were 50.32 
(SD±11.6) compared to 65.42 (SD±13.6) with the p-value of 0.0001 and 
ECOG scores were 2.54 (SD±0.85) compared to 1.78 (SD±0.92) with p-value 
of 0.0001 [11]. HRQoL was not reported in any of the studies. The fact that 
only two studies reported on QoL and no studies on HRQoL is particularly 
problematic with respect to mCRPC because QoL is of particular importance 
for end stage PC patients where palliation is a therapeutic aim. Patients with 
mCRPC report significantly worse QoL than other PC patients, owing to 
pain, fatigue, and decreased physical activity [46]. 
Pain scores reported on the VAS scale (11 point scale that goes from 0 no pain 
to 10 maximum pain) were addressed in two studies [11, 13]. In one study, 
VAS was reported on six patients only, where 33.3% of patients improved, 
66.6% remained the same, and no patients deteriorated [13]. Another study 
reported the VAS score as mean score between baseline and three months af-
ter the last 177Lu-PSMA cycle follow-up scoring 7.5 (SD±1) compared to 3 
(SD±0.9) with p-value of 0.0001 [11]. Concerning the minimum clinically 
important difference (MCID) on the VAS, a systematic review concludes that 
the threshold lies between 0.8 and 4 points (cm of improvement measured 
on the VAS scale) and hence the difference of 4.5 points from above lies near 
the upper limit of the threshold [47]. Concerning the BPI-SF pain score, it 
improved in pain severity at three months post last treatment cycle com-
pared to baseline by 1.1 points (95% CI: 1.9 to 0.4) and in pain interference 
by 1.0 points (95% CI: 1.9 to 0.1) [11]. The improvements reached however, 
do not seem to reach the MCID as in patients with bone metastases, MCID 
in BPI-SF ranges depending on the response to treatment. An improvement 
of 1.9 to 4.0 units could indicate minimal clinical significance in patients 
with complete or partial response, whereas the minimal change ranged from 
1.7 to 3.8 units for patients with indeterminate response [48].  
With respect to surrogate outcomes, median PFS was reported in two studies 
where it was 13.4 months [13] and 12 months [11]. RECIST score was report-
ed in four studies in the form of respond/stabilize/progress [10, 12-14]. The 
category of respond ranged from 20-60% of patients, stabilize from 0-52%, 
and progress from 27-30%. One study used the PERCIST tool instead and 
reported it on six patients where 33% had complete remission, 50% had par-
tial remission, and 16.6% had stable disease [11]. PSA PFS was reported on-
ly in one study and it was median 7.6 months (95% CI: 6.3-9) [12]. 
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Limitation of evidence 
The evidence found only partially answered our research questions. The pro-
spective observational evidence found can only contribute to the safety as-
sessment, yet still with a low to very low quality of evidence. RCTs or CTs 
comparing 177Lu-PSMA to alternative treatment options are thus necessary. 
However, choosing the right comparator presents a challenge. On the one 
hand, 177Lu-PSMA, as an experimental therapy, is to be used after the ex-
haustion of all therapeutic options (as it was the case in the studies included 
in the analysis), yet on the other hand, German AWMF S3 guideline includes 
177Lu-PSMA in the category of second line therapies [22]. Currently, there 
are two ongoing RCTs where one is comparing 177Lu-PSMA to the second 
line chemotherapy of cabazitaxel (NCT03392428) and the other to best sup-
porting care (NCT03511664). Both studies have its primary completion date 
in 2020 (see Table A-4). Furthermore, there are six more ongoing prospec-
tive studies on 177Lu-PSMA and a number of studies examining the use of 
177Lu-PSMA when combined with immunotherapy such as J591 antibody or 
pembrolizumab.  
 
RCTs sind notwendig, 
um 177Lu-PSMA  
mit anderen 
Therapiemöglichkeiten 
zu vergleichen und 
Aussagen zur 
Wirksamkeit treffen  
zu können  
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9 Recommendation 
In Table 9-1 the scheme for recommendations is displayed and  
the according choice is highlighted. 
Table 9-1: Evidence based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
 The inclusion in the catalogue of benefits is recommended with restrictions. 
x The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The current evidence is not sufficient to prove that the assessed technology 
177Lu-PSMA is more effective and equally safe or equally effective, but saf-
er than the comparators of best supportive care or the second line therapies: 
hormonal therapy, chemotherapy, immunotherapy, radiopharmaceuticals, or 
steroids. New study results will potentially influence the effect estimate con-
siderably. 
The re-evaluation is recommended in 2021 after the completion of two ongo-
ing RCTs (NCT03392428, NCT03511664). 
 
 
Empfehlungsschema 
Evidenz unzureichend 
 177Lu-PSMA derzeit 
nicht empfohlen 
Re-Evaluierung nach 
2021 empfohlen, wenn 
die derzeit laufende 
RCTs abgeschlossen sind  
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Appendix 
Evidence tables of individual studies included for clinical effectiveness and safety 
Table A-1: 177Lu-PSMA: Results from observational studies 
Author, year Baum et al. [13] (2016) Hofman et al. [12] (2018) Scarpa et al. [14] (2017) Yadav et al. [11] (2016) Emmet et al. [10] (2018) 
Country Germany Australia Austria India Australia 
Sponsor unclear1 Peter MacCallum Foundation, 
Prostate Cancer Foundation2 
University of Innsbruck 
and Medical University  
of Innsbruck3 
none Paul Ramsey Foundation 
Study design Prospective single centre 
before-after study 
Prospective single centre  
before-after study 
Prospective single centre 
before-after study 
Prospective single 
centre before-after study 
Prospective  
before-after study 
Conducted in 05/2013 – 06/2015 08/2015-12/2016 NA 2014-2016 NA 
Indication mCRPC mCRPC mCRPC mCRPC mCRPC 
Intervention Intravenous  
177Lu-PSMA-I&T 
Intravenous  
177Lu-PSMA-DKFZ-617 
Intravenous  
177Lu-PSMA-617 
Intravenous  
177Lu-PSMA- DKFZ-617 
Intravenous  
177Lu-PSMA-DKFZ-617 
 Strength of radiation,  
GBq (range) 
median 5.76 (3.6-8.7) mean 7.5 (4.4-8.7)4 mean 6.1 (5.4-6.5) mean 5.07 (SD±1.85) mean 7 (6-8)5 
 Total number of cycles  1256 96 29 66 42 
 Average number of cycles 
per patient, n 
2.2 3.2 2.9 2.1 3 
Comparator none none none none none 
Number of pts  567 308 10 319 1410 
                                                             
  1 Member of the authoring team is a shareholder at Scintomics, Germany. 
  2 Study supported by the Peter MacCallum Foundation and Prostate Cancer Foundation. Two members of the authoring team have conflicts of interest.  
One has received fees from the 177Lu PSMA manufacturer Endocyte®. 
  3 Funding the open access of the manuscript. 
  4 Adjusted according to tumor burden, patient weight, and renal function.  
  5 Adjusted according to a combination of eGFR, pt weight, and the number of sites of metastatic disease. 
  6 Discrepancy in the total number of cycles as the indicated total is 125, yet the sum of all the listed cycles is 131  
(see: 1 cycle in 16 pts, 2 cycles in 15 pts, 3 cycles in 17 pts, 4 cycles in 6 pts, 5 cycles in 2 pts). 
  7 At the time of analysis, data on 25 pts. 
  8 43 pts screened, 30 eligible for treatment. 
  9 36 pts screened, 31 eligible for treatment. 
10 18 pts screened, 14 eligible for treatment. 
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Author, year Baum et al. [13] (2016) Hofman et al. [12] (2018) Scarpa et al. [14] (2017) Yadav et al. [11] (2016) Emmet et al. [10] (2018) 
Imaging procedure used  68Ga-PSMA PET/CT 68Ga-PSMA-11 PET CT, 18F-FDG 
PET/CT, 51Cr-EDTA GFR, 
radionuclide bone scan,  
CT of the chest/abdomen/pelvis 
68Ga-PSMA-HBED-CC, 
17F-NaF PET/CT 
68Ga-PSMA-HBED-
CCPET/CT 
68Ga-HBEDD-PSMA-11 PET CT, 
18F-FDG PET/CT, bone scan, 
CT of the chest/abdomen/pelvis 
Inclusion criteria PSMA expression, 
exhaustion of all 
therapeutic options 
PSMA expression, exhaustion of 
most therapeutic options, life 
expectancy <12 weeks, ECOG ≤2, 
pathologically confirmed mCRPC, 
PSMA PET/CT demonstrating uptake 
intensity significantly greater than 
liver at sites of disease,  
PC progression within last 12 months 
as defined by RECIST or new 
metastases on a bone scan or new 
pain in an area of radiographically 
evident disease11 
PSMA expression, 
exhaustion of all 
therapeutic options 
PSMA expression, 
exhaustion of all 
therapeutic options 
PSMA expression, exhaustion 
of all therapeutic options, 
confirmed disease 
progression (new sites on CT 
and bone scan or rising PSA on 
3 occasions), life expectancy 
>12 weeks, ECOG score ≤ 2, 
platelet count ≥ 75,000 x 
109/L, haemoglobin ≥ 9.0 g/dL, 
albumin ≥ 25, neutrophil 
count ≥ 1.5 x109 and an  
eGFR ≥ 40 ml/min. 
Exclusion criteria NA Clinically significant impaired bone 
marrow, kidney (estimated GFR  
< 40 ml/min, hydronephrosis), liver 
function (albumin <= 25), poor 
blood counts (platelet count  
< 75,000 x10^9/L, neutrophil count 
< 1.5 x 10^9/L, or Hb < 9.0 g/dL), 
the use of concomitant nephrotoxic 
drugs, radiotherapy within 6 wks, 
uncontrolled intercurrent illness11 
NA Pts with Hb < 10 gp, 
platelet count  
< 60,000/mm3, 
TLC<4,000/mm3, serum 
creatinine>1.3 mg%, 
serum bilirubin >1.2 mg%, 
and GFR <60 mL/ 
min/1.73 m2 BSA,  
KPS<30 
Inadequate marrow  
function 
Co-interventions12 NA Blood transfusions, 
bisphosphonates, palliative 
radiotherapy,  
2nd generation anti-androgens 
NA kidney protection 
cocktail of lysine and 
arginine diluted in 2 L  
of normal saline 
14 (100%) pts on LHRH 
agent and 6 (43%) pts on 
denosumab/bisphosphonate 
treatments 
Age, yrs (range) median 72 (50-88) median 71 (IQR 67-75) median 67 (56-82) mean 65.9 (38-81) median 69.5 (56-81) 
Gleason score, n median 8 median 8 (IQR 7-9) ≥813 unclear14 median 9 (range 8-9) 
ECOG performance status 
(0/1/2), n (%) 
NA 11(37)/14(47)/5(17) NA mean 2.5415 5(35.7)/9(64.3)/0 
                                                             
11 Added from the registry website: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368970. 
12 Imaging was not understood as a co-intervention due to the low dose of radioisotopes administered. 
13 Not specified in statistical terms. 
14 Gleason score values cannot be understood from the table. It is assumed that 7 pts had a score of 6-7 and 24 pts a score pf 8-10. 
15 Reported as a mean and not in the ECOG categories of 0/1/2. 
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Author, year Baum et al. [13] (2016) Hofman et al. [12] (2018) Scarpa et al. [14] (2017) Yadav et al. [11] (2016) Emmet et al. [10] (2018) 
Tumor stage 
(pT1/pT2/pT3/pT4), n (%) 
1(1.8)/13(23.2)/35(62.5)/ 
7(12.5) 
unclear16 NA NA unclear17 
Previous interventions, n (%) 
 Hormone therapy 
 Luteinizing hormone-
releasing hormone analogs 
 
56 (100) 
56 (100) 
 
NA 
NA 
 
NA 
10 (100)18 
 
12 (38.7)19 
NA 
 
NA 
14 (100) 
 Surgical therapy 
 Prostatectomy 
 Orchiectomy (bilateral) 
 
40 (71.4) 
NA 
 
NA 
NA 
 
7 (70) 
NA 
 
7 (22.6)20 
25 (80.6) 
 
NA 
NA 
 External beam radiation 47 (83.9) NA 4 (40) 1 (3.2) 8 (57) 
 Chemotherapy 25 (44.6) 26 (87)21 3 (30)22 30 (96.7)23 10 (71)24 
 Antiandrogens 
 Cyproterone 
 Bicalutamide 
 Abiraterone 
 Enzalutamide 
 Detasteride 
 
17 (30.4) 
26 (46.4) 
21 (37.5) 
11 (19.6) 
NA 
 
NA 
NA 
25 (83)25 
see above 
NA 
 
0 
3 (30) 
2 (20) 
4 (40) 
NA 
 
NA 
NA 
NA 
NA 
NA 
 
NA 
10 (71) 
14 (100)26 
14 (100) 
NA 
 Bone interventions  
 223Ra-chloride 
 Bisphosphonate or 
denosumab 
 
1 (1.8) 
NA 
 
NA 
22 (73) 
 
3 (30) 
5 (50) 
 
NA 
NA 
 
NA 
7 (50) 
 Toxicity at baseline, n (%) NA NA NA 10 (32.3)27 NA 
                                                             
16 ≤20 metastases in 2 pts (7%), and >20 metastases in 28 pts (93%). 
17 Extent at diagnosis: localized in 8 (57%) pts and de novo metastatic in 6 (43%) pts. 
18 Hormone therapy used: degarelix in 3 (30%) pts, leuprorelin in 6 (60%) pts, goserelin in 1 (10%) pts, tamoxifene in 1 (10%) pts, and pamorelin in 2 (20%) pts. 
19 9 pts on hormonal therapy and chemotherapy and 3 pts on hormonal therapy, chemotherapy and 177Lu-EDTMP. 
20 5 pts with prostatectomy and 2 pts with prostatectomy and nodal dissection. 
21 Docetaxel in 24 (80%) and cebazitaxel in 14 (47%) pts. Also, 12 pts (40%) on 1 chemotherapy regimen, 12 (40%) on 2 chemotherapy regimens, 2 pts (7%) on ≥3 chemotherapy regimens. 
22 Docetaxel in 1 (10%) and taxotere in 2 (20%) pts. 
23 10 pts with chemotherapy alone, 8 pts with chemotherapy combined with radiotherapy, 9 pts with chemotherapy combined with hormonal therapy,  
and 3 pts with chemotherapy combined with hormonal therapy and 177Lu-EDTMP 
24 Docetaxel in 9 (64%) pts and cebazitaxel in 6 (43%) pts. 
25 Reported as abiraterone or enzalutamide or both. 
26 Only the use of abiraterone or enzalutamide are reported. Also, 7 pts (50%) received both interventions. 
27 Grade 1 hemoglobin toxicity. 
  
177Lu
-P
SM
A
 T
h
erap
y in
 P
atien
ts w
ith
 M
etastatic C
astratio
n
-R
esistan
t P
ro
state C
an
cer 
4
8
 
LB
I-H
T
A
| 20
19
 
Author, year Baum et al. [13] (2016) Hofman et al. [12] (2018) Scarpa et al. [14] (2017) Yadav et al. [11] (2016) Emmet et al. [10] (2018) 
Follow-up time, mo  median 15 (range 6-28) median 25 (IQR 12.7-25.2) unclear28 mean 13 (range 12-35) unclear 
Loss to follow-up, n (%) unclear29 unclear NA NA 5 (35.7)30 
Efficacy 
OS, in mo not reached at 15.5 
follow-up 
median 13.5 (95% CI: 10.4-22.7) NA median 16 mean 12.5 (± 33 weeks)31 
QoL 
 EORTC-QLQ-C30, mean 
difference in score 3 mo 
after last cycle vs baseline 
 
NA 
 
mean 0 (95% CI: –9 to 8) 
 
NA 
 
NA 
 
NA 
 KPS, mean n ±SD, mean 
score, 3 mo after last cycle 
vs baseline 
NA NA NA 50.32±11.6 vs 65.42±13.6 
(p=0.0001) 
NA 
 ECOG, mean n ±SD,  
mean score, 3 mo after  
last cycle vs baseline 
NA NA NA 2.54±0.85 vs 1.78±0.92 
(p=0.0001) 
NA 
HRQoL NA NA NA NA NA 
Pain score 
 VAS, 
%(improved/remained/ 
worsened) 
 
33.3/66.6/032 
 
NA 
 
NA 
 
7.5±1 vs 3±0.933 
(p<0.0001) 
(mean score baseline 
vs 3 mo after last 
cycle±SD) 
 
NA 
 BPI-SF (improvement 3 mo 
vs baseline) 
 Pain severity 
 Pain interference 
 
 
NA 
NA 
 
 
1.1 (95% CI: 1.9 to 0.4) 
1.0 (95% CI: 1.9 to 0.1) 
 
 
NA 
NA 
 
 
NA 
NA 
 
 
NA 
NA 
PFS, median mo 13.734 NA NA 12 NA 
                                                             
28 It is reported that follow-up was until death, while the time point at which death occurred is not reported. 
29 Analysis done of 25/56 pts at 15 mo follow-up, yet 12 pts died before 28 mo follow-up. 
30 5/14 pts did not complete follow-up due to poor clinical condition and travel distance to facility. 
31 56 ± 38 in responders vs. 36 ± 8 non-responders 
32 Reported on 6/56 pts. 
33 VASmax scale used, yet the description of VAS and VASmax read identical. 
34 Unclear if PFS was measured radiographically as figure 7 refers to radiographic PFS, while the text only mentions PFS. 
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Author, year Baum et al. [13] (2016) Hofman et al. [12] (2018) Scarpa et al. [14] (2017) Yadav et al. [11] (2016) Emmet et al. [10] (2018) 
RECIST35, n (%) 
(respond/stabilize/progress) 
5(20)/13(52)/7(28) 12(40)/0/8(27)36 6(60)/1(10)/3(30)37 NA38 7(50)/NA/NA 
PSMA PFS, median (95% CI)  
in mo 
NA 7.6 (6.3-9) NA NA NA 
Safety 
SAEs, n (%) 
 Study related death 
 
0 
 
039 
 
NA 
 
NA40 
 
NA 
AEs, n (%) 
 Grade 3 and 4 toxicities 
     
 Nephrotoxicity 0 0 0 0 NA 
 Hematotoxicity 
 Lymphocytopenia 
 Thrombocytopenia 
 Anaemia 
 Neutropenia 
 Haemoglobin  
 
0 
0 
0 
0 
NA 
 
11 (37) 
4 (13)41 
4 (13) 
2 (7) 
NA 
 
0 
0 
0 
0 
NA 
 
NA 
NA 
NA 
NA 
1 (3.2) 
 
NA 
0 
0 
NA 
NA 
 Hepatotoxicity NA NA 0 0 NA 
 Bone pain flare NA 1 (3) NA NA NA 
 Discontinuation rate NA 0 NA NA NA 
Abbreviations: AE – adverse event, BFI – Brief Pain Inventory, BSA – body surface area, CI – confidence interval, CT – computed tomography, ECOG – Eastern Cooperative Oncology Group, 
EDTA – ethylenediaminetetraacetic acid, EDTMP – ethylenediaminetetramethylene phosphonic acid, eGFR – (estimated) Glomerular Filtration Rate, EORTC-QLQ-C30 – European Organisation 
for Research and Treatment of Cancer Quality of Life Questionnaire, dL – decilitre, FDG – fluorodeoxyglucose, HBED CC – N,N'-bis (2-droxybenzyl) ethylenediamine-N,N'-diacetic acid, L – litre, 
LHRH – Luteinizing hormone-releasing hormone, IQR – interquartile range, KPS – Karnofsky Performance Status, mCRPC – metastatic castration resistant prostate cancer, mg – milligram, min – minute, 
mL – millilitre, mm – millimetre, mo – month, n – number, NA – not available, NaF – sodium fluoride, OS – overall survival, PET – positron emission tomography, PFS – progression free survival, 
PSMA – prostate specific membrane antigen, PSA PFS – prostate-specific antigen progression free survival, pts – patients, RECIST – Response Evaluation Criteria in Solid Tumours, QoL – quality  
of life, VAS (max) – Visual Analogue Scale, SAE – serious adverse event, SD – standard deviation, 68GA – Gallium, 17F –Fluorine, 51Cr – Chromium, 223Ra – Radium, 177Lu – lutetium 
                                                             
35 PET/CT measured. 
36 Assessed at 3 mo and not performed in 10 pts (33%) (due to clinical progression or death). 
37 Mixed response (disappearance and/or decrease of uptake of some lesions next to appearance of new lesions) in 3 pts. 
38 Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) tool used instead of RECIST in 6 pts: 2 pts with complete remission,  
3 pts with partial remission, and 1 pt with stable disease. 
39 No death was judged to be study related, yet 22 (73%) of pts were deceased at the time of data cut-off. 
40 5 pts (16.1%) died from due to disease. 
41 In 8 pts in total, but 4 in pts with unequivocal marrow progression. 
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Risk of bias table 
Table A-2: Risk of bias – study level (case series), see [4] 
Study  
reference/ID 
Baum et al.,  
2016, [13] 
Hofman et al., 
2018, [12] 
Scarpa et al.,  
2017, [14] 
Yadav et al.,  
2017, [11] 
Emmet et al.  
2018, [10] 
Study objective 
1. Was the hypothesis/aim/objective of the study clearly stated? Yes Yes  Yes Yes Yes 
Study design 
2. Was the study conducted prospectively? Yes Yes  Yes Yes Yes 
3. Were the cases collected in more than one centre? No No No No Unclear 
4. Were patients recruited consecutively? Unclear Unclear  Yes Unclear Unclear 
Study population 
5. Were the characteristics of the participants included in the study described? Yes Yes  Yes Yes Yes 
6.  Were the eligibility criteria (inclusion and exclusion criteria) for entry into the study clearly stated? Partial42 Yes Partial43 Partial44 Yes 
7. Did participants enter the study at similar point in the disease? Unclear45 Unclear45 Unclear45 Unclear45 Unclear45 
Intervention and co-intervention 
8. Was the intervention clearly described? Yes Yes  Yes Yes Yes 
9.  Were additional interventions (co-interventions) clearly described? No Yes No Partial Yes 
Outcome measure 
10. Were relevant outcome measures established a priori? Yes Yes Partial46 Yes Partial47 
11. Were outcome assessors blinded to the intervention that patients received? No No No No No 
12. Were the relevant outcomes measured using appropriate objective/subjective methods?  Yes Yes Partial48 Yes Partial48 
                                                             
42 Only the inclusion criteria were broadly stated in the study. 
43 Inclusion criteria were stated without the necessary detail and exclusion criteria were not state at all. 
44 Lack of detail in inclusion criteria. 
45 Not enough information about participants provided to make a judgment.  
46 Outcome measures with respect to QoL and OS were not stated. 
47 Outcome measures with respect to QoL were not stated. 
48 As some crucial outcomes were not measured at all, they could not be measured in appropriate ways. 
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51 
Study  
reference/ID 
Baum et al.,  
2016, [13] 
Hofman et al., 
2018, [12] 
Scarpa et al.,  
2017, [14] 
Yadav et al.,  
2017, [11] 
Emmet et al.  
2018, [10] 
13. Were the relevant outcomes measured before and after intervention? Yes Yes  No49 Yes Yes50 
Statistical Analysis 
14. Were the statistical tests used to assess the relevant outcomes appropriate? Yes Yes  Yes Yes Partial51 
Results and Conclusions 
15. Was follow-up long enough for important events and outcomes to occur?  No Yes Unclear52 Yes Unclear52 
16. Was the loss to follow-up reported? Unclear53 No No No Yes  
17. Did the study provide estimates of random variability in the data analysis of relevant outcomes?  No Yes  No Partial54 Yes 
18.  Were adverse events reported? Yes Yes  Yes Yes Yes 
19. Were the conclusions of the study supported by results? No55 No56  Yes No55 Yes  
Competing interest and source of support 
20. Were both competing interest and source of support for the study reported? Partial57 Yes  Partial57 Yes Partial58 
Overall Risk of bias High Low High Medium Medium 
 
 
                                                             
49 No crucial efficacy outcome was measured in the study and hence not measured before and after the intervention. 
50 QoL was not measured in the study and hence not measured before and after the intervention. 
51 OS reported as a mean instead of the common reporting in median. 
52 The length of follow-up was not clearly reported. 
53 There was a discrepancy between the total number of patients and the patients included in the analysis. 
54 CI for PFS and OS are missing. 
55 The study design cannot meet the conclusions about effectiveness. 
56 The study design cannot meet the conclusions about effectiveness and the conclusions are only made on the basis of a subgroup of patients from the results. 
57 Source of support was not clearly reported. 
58 Conflict of interests was not clearly reported. 
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Applicability table 
Table A-3: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population The population enrolled in the studies is similar to the target population of the intervention in that 
metastatic castration-resistant prostate cancer patients with overexpressed prostate specific membrane 
antigen (PSMA) are included. In all studies, 177Lutetium (Lu)-PSMA was applied after the exhaustion 
of all therapeutic options. However, in clinical practice, it is unclear whether 177Lu-PSMA is supposed 
to be second, third, or fourth line therapy option.  
Intervention Lu-177-labelled PSMA inhibitor therapy administered intravenously is the intervention at stake. 
PSMA can be also called folate hydrolase I or glutamate carboxypeptidase II. In the studies included 
in this assessment, the different types of radioligand therapy labelling include three ways of chemical 
conjugation of a peptide: 177Lu-PSMA-DKFZ-617, 177Lu-PSMA-I&T, and 177Lu-PSMA-617. In clinical 
practice, own radioligand agents can also be prepared by hospital radiologists.  
Comparators The comparators include best supportive care on the one hand and, as suggested by the German 
AWMF S3 guidelines, second line therapy options on the other hand: hormonal therapy options  
with abiraterone or enzalutamide; chemotherapy options of docetaxel + prednisone, cabazitaxel, 
mitoxantrone, and estramustine; immunotherapy options of sipuleucel-T; radiopharmaceutical 
option of radium 223; and steroids such as dexamethasone, prednisolone, prednisone. 
Outcomes Clinical effectiveness outcomes considered crucial in this assessment were: overall survival; health 
related quality of life (HRQoL) reported through Functional Assessment of Cancer Therapy – Prostate 
cancer score; quality of life (QoL) reported through the scoring charts of the European Organisation 
for Research and Treatment of Cancer, Eastern Cooperative Oncology Group, Karnofsky Performance 
Status; and pain scores reported through Brief Pain Inventory Short-Form and the Visual Analogue 
Scale. Of these, the most frequently reported was overall survival, while no HRQoL score was 
reported, and QoL was reported in two studies.  
Concerning surrogate outcomes used for the assessment of clinical effectiveness, progression free 
survival (PFS), Response Evaluation Criteria in Solid Tumors (RECIST) response, and Prostate Specific 
Antigen (PSA) PFS were used. Most frequently repoted was RECIST response. 
Safety outcomes considered were serious adverse event of study related death, adverse events of 
grade 3-4 toxicities, and discontinuation rates. Grade 3-4 toxicities were most frequently reported. 
Setting All the studies included were conducted in the inpatient setting in the countries of Germany, 
Australia, Austria, and India. The settting is thus similar to the Austrian one, however, 177Lu-PSMA 
may be also used in the outpatient setting in Austria, yet no data were reported from this contet. 
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List of ongoing randomised controlled trials 
Table A-4: List of ongoing randomised controlled trials of 177Lu-PSMA 
Identifier/ 
Trial name 
Patient 
population Intervention Comparison Primary Outcome 
Primary 
completion date Sponsor 
NCT03454750 210 mCRPC pts 177Lu PSMA 617 NA Disease control rate; 
Incidence of treatment-emergent AEs 
April 2020 Istituto Scientifico Romagnolo  
per lo Studio e la cura dei Tumori 
NCT03780075 30 mCRPC pts 177Lu-EB-PSMA617 NA Change of the PSA; 
Standardized uptake value of  
68Ga-PSMA before and after the 
treatment 
December 2019 Peking Union Medical College 
Hospital|National Institute for 
Biomedical Imaging and 
Bioengineering (NIBIB) 
NCT03403595 30 mCRPC pts 177Lu-EB-PSMA617 NA Standardized uptake value of  
177Lu-EB-PSMA617 in normal organs 
December 2018 Peking Union Medical College 
Hospital|National Institute for 
Biomedical Imaging and 
Bioengineering (NIBIB) 
NCT03392428 
ACTRN12617001590358 
200 mCRPC pts 177Lu-PSMA617 Cabazitaxel Prostate Specific Antigen response rate December 2020 Australian and New Zealand 
Urogenital and Prostate Cancer Trials 
Group|Australian Nuclear Science 
and Technology Organisation 
(ANSTO)|Endocyte®|Prostate 
Cancer Foundation of Australia 
(PCFA)|Australasian 
NCT03511664 
EUCTR2018-000459-41-DK 
EUCTR2018-000459-41-FR 
EUCTR2018-000459-41-SE 
750 mCRPC pts 177Lu-PSMA-617 Best 
supportive 
care 
Overall Survival August 2020 Endocyte® 
NCT03042312 72 mCRPC pts 177Lu-PSMA-617 NA Decline in tumor marker level (PSA) 
≥50% at 12 weeks 
February 2019 Endocyte® 
IRCT20180113038331N1 20 mCRPC pts 177Lu-PSMA NA Change the number of metastases  
after 3 cycles of therapy 
NA Mashhad University of  
Medical Sciences 
DRKS00013665 40 mCRPC pts 177Lu-PSMA NA Evaluation of serologic and imaging 
response to Lutetium-177-PSMA 
NA Universitätsklinikum Freiburg 
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Literature search strategies 
Search strategy for Cochrane 
Search Name: Lutetium for Prostate Cancer (MS/NG) 
Last Saved: 14/12/2018 20:44:07 
Comment: prelim MEL (2019) search 141218 
ID Search 
#1 MeSH descriptor: [Prostatic Neoplasms] explode all trees 
#2 (prostat* NEAR (cancer* or tumor* or tumour* or carcinom* or adenom* or adenoc* or adeno-c* or 
neoplasm*)):ti,ab,kw (Word variations have been searched) 
#3 #1 OR #2 (Word variations have been searched) 
#4 MeSH descriptor: [Lutetium] explode all trees 
#5 (lutetium) (Word variations have been searched) 
#6 (Lu* NEAR (177 OR 617 OR I&T OR PSMA)) (Word variations have been searched) 
#7 (PSMA NEAR (Lu* OR 177 OR 617 OR I&T)) (Word variations have been searched) 
#8 (J591) (Word variations have been searched) 
#9 MeSH descriptor: [Prostate-Specific Antigen] explode all trees and with qualifier(s): [therapeutic use - TU] 
#10 (radioligand*) (Word variations have been searched) 
#11 #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 (Word variations have been searched) 
#12 #3 AND #11 (Word variations have been searched) 
Total: 42 Hits 
 
 
Search strategy for CDR 
Search Name: Lutetium for Prostate Cancer (MEL 2019) 
Search Date: 17.12.2018 
ID Search 
#1 MeSH DESCRIPTOR Lutetium EXPLODE ALL TREES 
#2 (Lutetium) 
#3 (Lu* NEAR (177 OR 617 OR I&T OR PSMA)) 
#4 #1 OR #2 OR #3 
Total:1 Hit 
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Search strategy for Medline 
Search Name: Lutetium for Prostate Cancer (MEL 2019) 
Search Date: 17.12.2018 
ID Search 
#1 exp Prostatic Neoplasms/ (117325) 
#2 (prostat* adj5 (cancer* or tumo?r* or carcinom* or adenom* or adeno?c* or neoplasm*)).mp. (157312) 
#3 1 or 2 (157312) 
#4 exp Neoplasm Metastasis/ (190047) 
#5 metasta*.mp. (519720) 
#6  ((castrat* or hormon*) adj resist*).mp. (8959) 
#7 androgen* insensitiv*.mp. (3221) 
#8 4 or 5 or 6 or 7 (534695) 
#9 3 and 8 (36462) 
#10 exp Prostatic Neoplasms, Castration-Resistant/ (2662) 
#11  ((((castrat* or hormon*) adj resist*) or (metasta* or androgen* insensitiv*)) adj5 (prostat* adj5 (cancer* or 
tumo?r* or carcinom* or adenom* or adeno?c* or neoplasm*))).mp. (19876) 
#12 CRPC.ti,ab. (2459) 
#13 CRPRC.ti,ab. (5) 
#14 HRPC.ti,ab. (671) 
#15 AIPC.ti,ab. (207) 
#16 9 or 10 or 11 or 12 or 13 or 14 or 15 (37089) 
#17 exp Lutetium/ (788) 
#18 lutetium*.mp. (1446) 
#19 (Lu* adj5 "177").mp. (1162) 
#20 17 or 18 or 19 (2067) 
#21 exp Prostate-Specific Antigen/ (23661) 
#21 (Prostat* adj5 Anti?gen*).mp. (36945) 
#22 PSMA*.mp. (3164) 
#23 folate hydrolas*.mp. (80) 
#24 exp Glutamate Carboxypeptidase II/ (1151) 
#25 glutamat* carboxypeptidas*.mp. (1250) 
#26 21 or 22 or 23 or 24 or 25 or 26 (38922) 
#27 20 and 27 (110) 
#28 (Lu* adj5 ("177" or "617" or I&T or PSMA)).mp. (21646) 
#29 (PSMA adj5 (Lu* or "177" or "617" or I&T)).mp. (278) 
#30 J?591.mp. (96) 
#31 exp *Prostate-Specific Antigen/tu [Therapeutic Use] (11) 
#32 radio?ligand*.mp. (28764) 
#33 "Therapeutic Use".fs. (2098775) 
#34 33 and 34 (948) 
#35 radioligand therap*.mp. (100) 
#36 28 or 29 or 30 or 31 or 32 or 35 or 36 (22833) 
#37 16 and 37 (289) 
#38 remove duplicates from 38 (288) 
#39 exp Prostatic Neoplasms/ (117325) 
Total: 228 hits 
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Search strategy for Embase 
Search Name: Lutetium for Prostate Cancer (MEL 2019) 
Search Date: 17 Dec 2018 
ID Search 
#1 'metastatic prostate cancer'/mj 
#2 'castration resistant prostate cancer'/mj 
#3 'hormone resistant prostate cancer'/mj  
#4 'androgen independent prostate cancer'/mj 
#5 crpc:ti,ab  
#6 crprc:ti,ab 
#7 hrpc:ti,ab 
#8 aipc:ti,ab  
#9 'prostate cancer'/exp 
#10 (prostat* NEAR/5 (cancer* OR tumor* OR tumour* OR carcinom* OR adenom* OR adenoc* OR 'adeno c*'  
OR neoplasm*)):ti,ab,de 
#11 #9 OR #10  
#12 'castration resistant':ti,ab,de  
#13 'hormone resistant':ti,ab,de 
#14 metasta*:ti,ab,de  
#15 'androgen* insensitiv*':ti,ab,de 
#16 #12 OR #13 OR #14 OR #15 
#17 #11 AND #16 
#18 (('castration resistant' OR 'hormon* resistant' OR metasta* OR 'androgen insensitiv*') NEAR/5 ('prostat* 
cancer*' OR 'prostat* tumor*' OR 'prostat* tumour*' OR 'prostat* carcinom*' OR 'prostat* adenom*' OR 
'prostat* adenoc*' OR 'prostat* adeno-c*' OR 'prostat* neoplasm*')):ti,ab,de 
#19 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #17 OR #18 
#20 'lutetium 177'/exp 
#21 (lutetium* NEAR/1 177):ti,ab,de 
#22 lu177:ti,ab,de 
#23 'lu 177':ti,ab,de 
#24 177lu:ti,ab,de 
#25 '177 lu':ti,ab,de 
#26 #20 OR #21 OR #22 OR #23 OR #24 OR #25 
#27 'prostate specific antigen'/exp 
#28 (prostat* NEAR/2 antigen):ti,ab,de 
#29 psma*:ti,ab  
#20 'folate hydrolase 1'/exp 
#31 'folate hydrolas*':ti,ab,de  
#32 'glutamate carboxypeptidase ii'/exp 
#33 'glutamate carboxypeptidas*':ti,ab,de 
#34 #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 
#35 #26 AND #34 
#36 'lutetium prostate specific membrane antigen 617 lu 177'/exp 
#37 (lu* NEAR/5 ('177' OR '617' OR i&t OR psma)):ti,ab,de 
#38 (psma NEAR/5 (lu* OR '177' OR '617' OR i&t)):ti,ab,de 
#39 'monoclonal antibody j591'/exp  
#40 j591:ti,ab,de 
#41  'prostate specific antigen'/exp/dd_dt 
Appendix 
LBI-HTA | 2019 57 
#42 'radioligand'/exp/dd_dt 
#43 ((radioligand* OR 'radio ligand*') NEAR/5 (therap* OR treat* OR regimen* OR program*)):ti,ab,de 
#44 #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 
#45 #19 AND #44 
#46 #19 AND #44 AND ([controlled clinical trial]/lim OR [randomized controlled trial]/lim) 
#47 'crossover procedure':de OR 'double-blind procedure':de OR 'randomized controlled trial':de OR 'single-blind 
procedure':de OR random*:de,ab,ti OR factorial*:de,ab,ti OR crossover*:de,ab,ti OR ((cross NEXT/1 
over*):de,ab,ti) OR placebo*:de,ab,ti OR ((doubl* NEAR/1 blind*):de,ab,ti) OR ((singl* NEAR/1 blind*):de,ab,ti) 
OR assign*:de,ab,ti OR allocat*:de,ab,ti OR volunteer*:de,ab,ti 
#48 #45 AND #47  
#49 'clinicaltrials gov'  
#50 #45 AND #49 
#51 #46 OR #48 OR #50 
Total: 378 hits 
 
 
Search strategy for ClinicaTrials.gov 
Date: 18/01/2019 
( Prostate Cancer OR Prostate Carcinoma OR Prostate Tumor OR Prostate Tumour OR Prostate 
Neoplasm OR Prostate Adenocarcinoma OR prostate OR prostatic ) [DISEASE] AND ( lutetium OR 
Lu177 OR lu 177 OR radioligand OR LuPSMA OR Lu-PSMA ) [TREATMENT] 
Total: 21 hits 
 
 
Search strategy for WHO-ICTRP 
Date: 18/01/2019 
Condition: Condition: Prostate Cancer OR Prostate Carcinoma OR Prostate Tumor OR Prostate 
Tumour* OR Prostate Neoplasm OR Prostate Adenocarcinoma OR prostate OR prostatic 
AND  
Intervention: lutetium OR Lu177 OR lu-177 OR radioligand OR LuPSMA OR Lu-PSMA 
Total: 23 (14 further) hits 
 
 
Search strategy for EU Clinical Trials (EUdraCT) 
Date: 18/01/2019 
prostat* AND (lutetium OR Lu177 OR lu-177 OR radioligand OR LuPSMA OR Lu-PSMA) 
Total: 3 (1 further/relevant)hits 
 
  
 
